Document:

Exhibit 10.2

 

Confidential Treatment Requested

by Celera Corporation

 

 

OPERATING AGREEMENT

 

BY AND BETWEEN

 

APPLERA CORPORATION

 

AND

 

CELERA CORPORATION

 

 

DATED AS OF 
[                   ], 2008

 

 

Confidential Treatment Requested

by Celera Corporation

 

TABLE OF CONTENTS

 

	
  ARTICLE I DEFINITIONS

  	
  2

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Section 1.1

  	
  Definitions

  	
  2

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE II GENERAL

  	
  4

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Section 2.1

  	
  Performance

  	
  4

  
	
   

  	
  Section 2.2

  	
  General Cooperation

  	
  4

  
	
   

  	
  Section 2.3

  	
  Research and Development Activities

  	
  4

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE III OPERATING PRINCIPLES

  	
  4

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Section 3.1

  	
  Capillary Electrophoresis Sequencers

  	
  4

  
	
   

  	
  Section 3.2

  	
  Kauai Project

  	
  5

  
	
   

  	
  Section 3.3

  	
  Next Generation Sequencing Technology

  	
  6

  
	
   

  	
  Section 3.4

  	
  Real-Time Instruments

  	
  6

  
	
   

  	
  Section 3.5

  	
  Reagents

  	
  8

  
	
   

  	
  Section 3.6

  	
  Maui Project

  	
  9

  
	
   

  	
  Section 3.7

  	
  Licenses and Licensing

  	
  10

  
	
   

  	
  Section 3.8

  	
  Applera Intellectual Property

  	
  10

  
	
   

  	
  Section 3.9

  	
  Application of Restrictions in Event of Acquisitions

  	
  11

  
	
   

  	
  Section 3.10 

  	
  Use and Restrictions of Confidential Information, Know-How and Trade
  Secrets

  	
  11

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE IV RELATIONSHIP TO OTHER DOCUMENTS

  	
  12

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE V DISPUTE RESOLUTION

  	
  13

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE VI INDEMNIFICATION

  	
  13

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE VII FORCE MAJEURE

  	
  13

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE VIII TERMINATION

  	
  13

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Section 8.1

  	
  Termination

  	
  13

  
	
   

  	
  Section 8.2

  	
  Termination for Default

  	
  13

  

 

 

i

 

Confidential Treatment Requested

by Celera Corporation

 

 

	
   

  	
  Section 8.3

  	
  Return or Destruction of Material

  	
  14

  
	
   

  	
  Section 8.4

  	
  Effect of Termination

  	
  14

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE IX OTHER REPRESENTATIONS, WARRANTIES AND COVENANTS

  	
  14

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Section 9.1

  	
  Compliance with Laws

  	
  14

  
	
   

  	
  Section 9.2

  	
  Books and Records

  	
  14

  
	
   

  	
  Section 9.3

  	
  No Other Representations or Warranties

  	
  14

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE X MISCELLANEOUS

  	
  15

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Section 10.1

  	
  Relationship of the Parties

  	
  15

  
	
   

  	
  Section 10.2

  	
  Employees of the Parties

  	
  15

  
	
   

  	
  Section 10.3

  	
  Notices

  	
  15

  
	
   

  	
  Section 10.4

  	
  Governing Law

  	
  16

  
	
   

  	
  Section 10.5

  	
  Parties in Interest; Assignment; Successors

  	
  16

  
	
   

  	
  Section 10.6

  	
  Entire Agreement

  	
  16

  
	
   

  	
  Section 10.7

  	
  Exhibits

  	
  16

  
	
   

  	
  Section 10.8

  	
  Waivers of Default

  	
  16

  
	
   

  	
  Section 10.9

  	
  Amendments

  	
  16

  
	
   

  	
  Section 10.10

  	
  Headings

  	
  16

  
	
   

  	
  Section 10.11

  	
  Severability; Enforcement

  	
  17

  
	
   

  	
  Section 10.12

  	
  No Third-Party Beneficiaries

  	
  17

  
	
   

  	
  Section 10.13

  	
  Remedies

  	
  17

  
	
   

  	
  Section 10.14

  	
  Expenses

  	
  17

  
	
   

  	
  Section 10.15

  	
  Counterparts

  	
  17

  
	
   

  	
  Section 10.16

  	
  No Set-Off

  	
  17

  
	
   

  	
  Section 10.17

  	
  Confidentiality

  	
  17

  
	
   

  	
  Section 10.18

  	
  Facilities and Systems Security

  	
  17

  
					

 

Exhibit A – Definition of HIVD Field

Exhibit B – Specified Country List

Exhibit C – Forensics and Applied
Markets

 

ii

 

Confidential Treatment  Requested

by Celera Corporation

 

OPERATING AGREEMENT

 

This Operating Agreement (this “Agreement”),
dated as of                 ,
2008 (the “Effective Date”), by and between Applera Corporation, a
Delaware corporation (“Applera”), and Celera Corporation, a Delaware
corporation (“Celera” and, collectively with Applera, the “Parties,”
and each individually, a “Party”).

 

R E C I T A L S

 

WHEREAS, prior to the Separation (as defined
below) Applera conducted its business through two business segments – the
Applied Biosystems Group, which primarily serves the life science industry,
research community and other markets, including human identity testing,
biosecurity, and quality and safety testing, by developing and marketing instrument-based
systems, consumables, software, and services (the “Applied Biosystems
Business”), and the Celera Group, which is primarily a human in vitro
diagnostics business that delivers personalized disease management through a
combination of products and services  (the “Celera
Business”); and

 

WHEREAS, the Board of Directors of Applera
has determined that it is advisable and in the best interests of Applera and
its stockholders to separate the Celera Group from Applera by way of a
redemption of all of the issued and outstanding Celera Group Common Stock
pursuant to Article IV, Section 2.4(d) of Applera’s Restated
Certificate of Incorporation (the “Separation”), so that, from and after
the date hereof, the Celera Business will be conducted through Celera, which
will be a separate, independent publicly traded company; and

 

WHEREAS, to effectuate the Separation, the
Parties have entered into that certain Separation Agreement dated as of May 8,
2008 (the “Separation Agreement”) setting forth, among other things, the
terms and conditions of the Separation (capitalized terms used herein but not
defined herein shall have the meanings set forth in the Separation Agreement);
and

 

WHEREAS, in connection with the Separation,
Applera intends to effect a name change from Applera Corporation to Applied
Biosystems Inc.; and

 

WHEREAS, in connection with the Separation,
Applera and Celera desire to enter into this Agreement to memorialize their
mutual understanding and agreement with respect to the conduct of certain
aspects of their businesses following the date hereof.

 

NOW, THEREFORE, in consideration of the
premises and the mutual covenants and agreements set forth herein and for other
good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties, intending to be legally bound hereby, agree
as follows:

 

1

 

Confidential Treatment  Requested

by Celera Corporation

 

ARTICLE I

DEFINITIONS

 

Section 1.1                                      Definitions.
For purposes of this Agreement, the following terms shall have the meanings set
forth below:

 

(a)                               “Abbott
Alliance” means the strategic alliance among Abbott Laboratories,
Applera, and Celera Diagnostics, LLC, pursuant to the Abbott Alliance
Agreement.

 

(b)                                 “Abbott Alliance Agreement”
means the Restated Strategic Alliance Agreement, effective as of January 9,
2006, among Applera, Celera Diagnostics, LLC, and Abbott Laboratories.

 

(c)                                  “Abbott Supply Agreement”
means the Abbott Real-Time PCR Instrument Supply Agreement, effective as of September 14,
2004, between Applera and Abbott Laboratories.

 

(d)                                 “ASR” means an analyte
specific reagent as defined under 21 CFR §864.4020(a), as the same may be
amended or replaced from to time.

 

(e)                                  “CE” means capillary
electrophoresis.

 

(f)                                    “CE-Marked” means CE marking
in accordance with the In Vitro Diagnostics Directive (IVDD) 98/79/EC.

 

(g)                                 “CE Assays” means consumable
products used on CE sequencers for HIV genotyping, HCV genotyping, HBV
genotyping, CF, Fragile X, and HLA typing assays for the analysis of nucleic
acids in the HIVD Field.

 

(h)                                 “CF” means cystic fibrosis.

 

(i)                                     “CT” means Chlamydia
trachomatis.

 

(j)                                     “Factor II” means
prothrombin, a protein involved in blood clotting, and the gene that encodes it
or a variant thereof.

 

(k)                                  “Factor V” means a protein involved
in blood clotting, and the gene that encodes it or a variant thereof, such as factor V Leiden.

 

(l)                                     “Fragile X” means Fragile X
syndrome.

 

(m)                               “GPR” or “General Purpose
Reagent” means a chemical or biological reagent that (i) is not an ASR
and (ii) has general laboratory application.

 

(n)                                 “Group” means either the
Applied Biosystems Group or the Celera Group.

 

(o)                                 “[***]” means [***].

 

(p)                                 “HBV” means hepatitis B
virus.

 

2

 

Confidential Treatment  Requested

by Celera Corporation

 

(q)                                 “HCV” means hepatitis C
virus.

 

(r)                                    “HIV” means human
immunodeficiency virus.

 

(s)                                  “HIVD Field” means the field
of human in vitro diagnostics as defined on Exhibit A
attached hereto.

 

(t)                                    “HLA” means human leukocyte
antigen.

 

(u)                                 “[***]” means [***].

 

(v)                                 “Kauai Project” means the
Celera instrument development project code-named “Kauai” by the Parties for
internal reference purposes.

 

(w)                               “Licensed IP” means any
Applera intellectual property previously licensed by Celera under the terms of (i) the
Real-Time Instrument Patent License Agreement, effective as of April 5,
2004, between Applera and Cepheid, (ii) the Real-Time Instrument Patent
License Agreement, effective as of April 25, 2006, and Diagnostics Field
DNA Sequencing Sublicense Agreement, effective as of April 25, 2006,
between Applera and Beckman Coulter, Inc., or (iii) the License
Agreement, effective as of July 1, 2007, and Sequence Analysis License
Agreement, effective as of April 20, 2000, between Applera and Siemens
Medical Solutions Diagnostics.

 

(x)                                   “Maui Assays” means
consumable products resulting from the Maui Project for HIV genotyping, HCV
genotyping, HBV genotyping, CF, Fragile X, and HLA typing assays for the
analysis of nucleic acids in the HIVD Field.

 

(y)                                 “Maui Project” means the
Applera instrument development project code-named “Maui” by the Parties for
internal reference purposes.

 

(z)                                   “[***]” means [***].

 

(aa)                                      “NG” means Neisseria
gonorrhoeae.

 

(bb)                                    “OEM” means a supply
arrangement whereby Applera supplies a product to a third party that (i) is
not a distributor, agent or wholesaler for Applera, and (ii) resells such
product.  A specific example of a company
that is not a distributor, agent or wholesaler for Applera is a company that
commercializes diagnostic products globally.

 

(cc)                                      “Real-Time Assays” means
real-time PCR-based assays for the analysis of nucleic acids of HIV, HCV, HBV, [***],
CT, NG, [***], and [***] in the HIVD Field.

 

(dd)                                    “Real-Time Instrument” means
a real-time PCR thermal cycler covered by the claims of US Patent No. 6,814,934.

 

(ee)                                      “Specified Countries” means
the countries and territories, as commonly recognized as of the Effective Date,
including any such country and territory as may be 

 

3

 

Confidential Treatment  Requested

by Celera Corporation

 

subsequently recognized by a different name,
set forth on the “Specified Country List” attached hereto as Exhibit B.

 

(ff)                                          “Specified Supplier” means
[***].

 

(gg)                                    “Supply Agreement” means that
certain Master Purchase Agreement between the Parties of even date with this
Agreement pursuant to which Applera is to supply certain products to Celera.

 

ARTICLE II

GENERAL

 

Section 2.1                                      Performance.  Applera and Celera hereby agree that each
Party shall use commercially reasonable efforts to take, or cause to be taken,
all actions, and to do, or cause to be done, all things necessary, proper or
advisable under applicable laws to comply with the terms of this Agreement,
including the operating principles set forth in Article III hereof.

 

Section 2.2                                      General
Cooperation.  Subject to the terms
and conditions set forth in this Agreement, Applera and Celera shall each use
commercially reasonable efforts to provide to the other Party any information
and documentation reasonably required in the performance of such other Party’s
obligations hereunder, and make available, as reasonably requested by the other
Party, sufficient resources and timely decisions, approvals and acceptances in
order that each Party may fulfill its obligations under this Agreement in a
timely and efficient manner.

 

Section 2.3                                      Research and
Development Activities.  Applera and
Celera agree that (i) the human in vitro diagnostics business of Celera
includes research and development activities toward commercialization of
products and services in the HIVD Field and (ii) the restrictions imposed
on Applera pursuant to this Agreement shall not prevent Applera from conducting
its own research and development activities in the HIVD Field at any time
during the term of this Agreement.

 

ARTICLE
III

OPERATING PRINCIPLES

 

Section 3.1                                      Capillary Electrophoresis Sequencers.

 

(a)                                  Abbott Alliance. 
From and after the Effective Date, Applera shall provide to Abbott
Laboratories (“Abbott”), as provided for in the Abbott Alliance
Agreement, and/or Celera the current (as of the Effective Date) CE sequencers
of Applera and associated consumables, in each case, as they have been provided
by Applera to Abbott and/or Celera in connection with the Abbott Alliance prior
to the Effective Date or as otherwise provided under a separate supply
agreement between Applera and Celera.

 

(b)                                 Rights of Celera. 
From and after the Effective Date and to the extent not otherwise
provided to Abbott and/or Celera, Applera shall provide Celera with CE
sequencers and associated consumables in the same manner as provided to other
third party customers of 

 

4

 

Confidential Treatment  Requested

by Celera Corporation

 

Applera.  In the event that Celera wishes to purchase
CE sequencers developed by Applera but not otherwise offered for sale, the
Parties shall negotiate in good faith the terms and conditions of such access.

 

(c)                                  Restrictions on Celera

 

(i)                                             Celera shall purchase CE sequencers
described in (a) and (b), above, and associated consumables, pursuant to
the Supply Agreement.

 

(ii)                                          Celera may only sell such CE
sequencers and associated consumables in the HIVD Field.

 

(d)                                 Rights of Applera. 
Applera may:

 

(i)                                   sell any CE sequencer to any end-user
for any purpose; and

 

(ii)                                OEM any CE sequencer to any customer
(an “OEM Customer”) for any purpose; provided, however,
that any such OEM Customer shall agree that it shall not commercialize any CE
Assay on such CE sequencer in any country or territory other than the Specified
Countries for a period of three (3) years following the Effective Date,
subject to Section 3.9(c) hereof.

 

(e)                                  Restrictions on Applera. 
Applera shall not:

 

(i)                                   [***];

 

(ii)                                commercialize any CE Assay for a
period of three (3) years following the Effective Date, subject to Section 3.9
hereof; or

 

(iii)                             enter into an agreement with a third
party to co-promote or co-market CE sequencers to be used with CE Assays, in
any country or territory other than the Specified Countries for a period of
three (3) years following the Effective Date, subject to Section 3.9
hereof.

 

Section 3.2                                    Kauai
Project.

 

(a)                                  Project Development. 
Celera may develop products under the Kauai Project that comply with the
requirements of the United States Food and Drug Administration (the “FDA”),
and shall pay all costs associated with meeting such requirements.  Celera and Applera shall enter into good
faith negotiations to conclude an agreement regarding the Kauai Project, on
mutually agreed upon terms, covering, among other things, support of Celera’s
development activities (“Kauai Agreement”).

 

 

5

 

Confidential Treatment  Requested

by Celera Corporation

 

 

(b)                                 Kauai Products.

 

(i)                                   The products resulting from the Kauai
Project shall be intended for use in the HIVD Field, but not intended for use
outside the HIVD Field.

 

(ii)                                Celera shall be the manufacturer of
record for products resulting from the Kauai Project.

 

(iii)                             Products resulting from the Kauai
Project may only be sold by Celera and only for use in the HIVD Field.

 

(iv)                            Except as otherwise agreed by the
Parties, Applera shall not sell any instrument resulting from the Kauai
Project.

 

(c)                                  Access to Specified
Supplier.  Applera agrees to use commercially
reasonable efforts to facilitate Celera access to the Specified Supplier for
the purpose of development and commercialization of products under the Kauai
Project.

 

(i)                                   In the event that Celera is legally
required to source products resulting from the Kauai Project directly from the
Specified Supplier, it shall be permitted to do so, and in such event Applera
shall be entitled to receive compensation from Celera in an amount equal to the
amount of incremental proceeds Applera would have received had the products been
sourced directly from it.  The amount of
such incremental proceeds would be calculated in accordance with the provisions
of the Kauai Agreement.

 

Section 3.3                                    Next Generation
Sequencing Technology.  It is the
intent and mutual understanding of the Parties that this Agreement shall not
constitute or be deemed to constitute any commitment or obligation for the
Parties to collaborate on any “next generation” sequencing instrument.  Specifically, this Agreement places no
restrictions whatsoever on either Party relating to the development or
commercialization of next generation sequencing instruments.

 

Section 3.4                                    Real-Time
Instruments.

 

(a)                                  Real-Time Instruments.

 

(i)                                   Except for the restrictions under
the Abbott Supply Agreement in effect as of the Effective Date or as such
agreement may be amended by the parties to that agreement with Celera’s
approval (not to be unreasonably withheld or delayed), Applera shall be
permitted to sell Real-Time Instruments, including instruments registered with
a regulatory authority, to any end user for any purpose; and

 

 

6

 

Confidential Treatment  Requested

by Celera Corporation

 

 

(ii)                                Except for the Abbott Supply
Agreement in effect as of the Effective Date or as such agreement may be
amended by the parties to that agreement with Celera’s approval (not to be
unreasonably withheld or delayed), Applera shall not OEM Real-Time Instruments
to any OEM Customer for use in the HIVD Field unless such OEM Customer has
obtained a license to the relevant

 

Licensed IP for real-time technology in the
HIVD Field; provided, however, that any such OEM Customer shall
also agree that it shall not commercialize any Real-Time Assay on such
Real-Time Instruments, unless otherwise agreed to by Applera and Celera, for a
period of three (3) years following the Effective Date, subject to Section 3.9(c)
hereof.

 

(iii)                             Applera shall not enter into an
agreement with a third party to co-promote or co-market Real-Time Instruments
to be used with Real-Time Assays,  in
any country or territory other than the Specified Countries for a period of
three (3) years following the Effective Date, subject to Section 3.9
hereof.

 

(b)                                 Preferred Supplier Designation. 
Applera will be the preferred supplier of Celera’s next generation
Real-Time Instrument, subject to the following terms and conditions:

 

(i)                                   The Parties agree to negotiate in
good faith the terms of a supply agreement for such instrument; and

 

(ii)                                If, after negotiating in good faith, the
Parties are unable to enter into such supply agreement within [***] following
receipt of a notice from Celera specifying the date on which the Parties shall
commence such negotiation (which date may not be prior to the date of the
notice), the Parties may agree to a [***] extension.  If the Parties are unable or unwilling to agree to an
extension or if no agreement is reached during any such extension, Celera shall
be granted [***] to all intellectual property owned by Applera and all
intellectual property which Applera has the right to sublicense (and Celera
shall bear the cost of any pass through royalties that would be associated with
that sublicense) as of the Effective Date that is necessary to make or to have
a next generation Real-Time Instrument made and supplied by a third party only
to Celera; provided, however, that the terms of any such
third-party supply relationship shall be no less favorable to Celera than the
terms last proposed by Applera; and, provided  further, that such
third party shall not be infringing or challenging any patents of Applera
related to such next generation real-time instruments at the time when Celera
enters into a supply agreement with such third party.

 

 

 

7

 

Confidential Treatment Requested

by Celera Corporation

 

Section 3.5                   Reagents.

 

(a)                                  Sequence Specific Primers and
Probes.  Applera agrees that it will not knowingly
commercialize any sequence-specific primers and probes (i) for
incorporation by a third party product manufacturer into its products for
performing testing in the HIVD Field or (ii) to a clinical laboratory for
performing home-brew testing, in either case, for HIV, HCV, HBV, [***], CT, NG,
Factor V, Factor II, [***], CF, HLA, Fragile X, and [***], for a period of
three (3) years following the Effective Date, subject to Section 3.9
hereof; provided, however, that:

 

(i)                                   Applera may request that Celera
waive this restriction for Applera to commercialize such primers and probes
during the three (3) year period following the Effective Date for specific
opportunities, it being understood that the decision to so waive this
restriction shall be made by Celera in its sole discretion;

 

(ii)                                Applera shall not be obligated to
actively monitor third party conduct for any inadvertent violation, but Applera
and Celera shall discuss an appropriate course of action upon notice from
Celera with reasonable evidence of violation of this provision or if Applera
otherwise becomes aware of such a violation; and

 

(iii)                             The restrictions set forth in this
Section 3.5 shall not apply to sales to any third party for sale or use
within any Specified Country.

 

(b)                                 Analyte Specific Reagents (ASRs). 
Applera shall not commercialize, directly or through a distributor, ASRs
or kits for performing human testing in the HIVD Field for HIV, HCV, HBV,
[***], CT, NG, Factor V, Factor II, [***], CF, HLA, Fragile X, and [***], for a
period of three (3) years following the Effective Date, subject to Section 3.9
hereof.

 

(c)                                  General Purpose Reagents (GPRs). 
This Agreement provides no restrictions or limitations on the ability of
Applera to sell GPRs.

 

(d)                                 Other Limitations.

 

(i)                                   Except for the rights granted
pursuant to the HLA License Agreement, Applera shall not have any rights to
Celera’s intellectual property assigned to it by Applera pursuant to the
Separation Agreement.  In the event that
Applera has a product that infringes Celera’s intellectual property, and upon
notice from Celera with reasonable evidence of unlicensed activity, Applera shall
stop selling such product.  Applera may
resume sales of such product if Applera or its customers are no longer (or are
not) infringing Celera’s intellectual property rights in the HIVD Field, unless
otherwise prohibited herein.

 

8

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

 

	
  (ii)

  	
  Celera shall not commercialize, directly or through a distributor,
  products in the forensics and applied markets listed on Exhibit C hereto
  that incorporate intellectual property owned by Applera or which Applera has
  the exclusive right to sublicense, unless Celera obtains a license directly
  or indirectly to the relevant intellectual property from Applera under
  standard third party terms to be mutually agreed upon.

  

 

Section 3.6               Maui
Project.

 

(a)                                                     Project Development. 
Products developed by Applera under the Maui Project need not be
submitted by Applera for registration with the FDA in the United States, but
may be registered with any other regulatory authority.  Furthermore, it is understood by the Parties
that any instrument developed under the Maui Project shall not be “Alliance
Products” or “Alliance Technology” (as such terms are defined in the Abbott
Alliance Agreement) and shall be treated within the Abbott Alliance in the same
manner as other similar products of Applera that are not “Alliance Products” or
“Alliance Technology.”

 

(b)                                                    Rights of Applera. 
In connection with the Maui Project, Applera shall be free to:

 

	
  (i)

  	
  sell any product resulting from the Maui Project to any end-user for
  any purpose; and

  
	
   

  	
   

  
	
  (ii)

  	
  OEM any product resulting from the Maui Project to any customer for
  any purpose; provided, however, that any such OEM Customer
  shall agree that it shall not commercialize any Maui Assay in any country or
  territory other than the Specified Countries for a period of three (3) years
  following the Effective Date, subject to Section 3.9(c) hereof.

  

 

(c)                                                     Restrictions on Applera. 
In connection with the Maui Project, Applera shall not:

 

	
  (i)

  	
  supply or OEM any instrument resulting from the Maui Project to
  Abbott other than through the Abbott Alliance; or

  
	
   

  	
   

  
	
  (ii)

  	
  commercialize the Maui Assays for a period of three (3) years
  following the Effective Date, subject to Section 3.9 hereof.

  

 

(d)                                                    Celera Rights and Restrictions. 
Celera may purchase products resulting from the Maui Project through the
Supply Agreement.  In addition, Celera
may only sell products resulting from the Maui Project for use in the HIVD
Field.

 

(e)                                  US FDA Cleared or Approved
Version of Maui.  Applera agrees that if it obtains FDA
clearance or approval on an instrument developed under the Maui Project in the
United States, or any instrument that is substantially based on the design and
throughput of an 

 

9

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

 

instrument developed under the Maui Project,
it will make such FDA cleared or approved version of the Maui product available
to Celera under the Supply Agreement.

 

Section 3.7             Licenses
and Licensing.

 

(a)                                                     Celera Licensing Rights. 
There shall be no restrictions on Celera’s ability to license any
intellectual property assigned to Celera by Applera as of the Effective Date.

 

(b)                                                    Licensed Intellectual Property. 
Subject to the following conditions, Celera and Applera shall work
together in good faith to license to third parties the Licensed IP in the HIVD
Field:

 

	
    (i)

  	
  All such licenses shall be consistent with existing licenses to the
  Licensed IP; provided, however, that the terms of a new HIVD
  Field license to an existing non-HIVD Field licensee shall use

  
	
   

  	
  language and terms that do not conflict with the terms (especially
  definitions of fields) of the existing license to said licensee.

  
	
   

  	
   

  
	
  (ii)

  	
  Celera  shall have
  primary responsibility for negotiation of the licenses, although Applera will
  be kept informed of, and have the right to participate in, all such
  negotiations.  Celera will provide
  Applera with reasonable prior notice of meetings, whether in person or by
  phone, with potential licensees. 
  Celera will also provide Applera with reasonable time to review
  documents prior to sending them to potential licensees.

  
	
   

  	
   

  
	
  (iii)

  	
  All revenue generated by such licenses shall be shared equally
  between Celera and Applera.

  
	
   

  	
   

  
	
  (iv)

  	
  The Parties have agreed on a list of approved licensees and a general
  framework for licenses.  Transactions
  by either Party with such licensees and consistent with such general
  framework shall not require any further approval of the other Party.  Other licensees and/or changes from the
  framework shall require approval of both Parties.

  
	
   

  	
   

  
	
  (v)

  	
  From and after the Effective Date, Celera and Applera shall share
  costs associated with the Licensed IP, which costs include maintenance,
  prosecution, enforcement, and defense costs, in such proportion as may be agreed
  by the Parties or as is necessary and appropriate to reflect the relative
  financial and other benefits received by each Party.  Any disagreement regarding the allocation
  of such costs shall be resolved in accordance with the dispute resolution
  procedures set forth in Article XIII of the Separation Agreement.

  

 

Section 3.8                                                Applera Intellectual Property. Except as otherwise provided
herein, ownership of, and all rights in all fields to, Applera intellectual
property shall remain with the 

 

 

10

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

Party that is the successor to the Group
(including by way of name change) responsible for prosecuting or maintaining
such intellectual property prior to the Separation.

 

Section 3.9                                      Application of Restrictions in Event
of Acquisitions.

 

(a)                                            Acquisition of Competing
Product.  Notwithstanding any other provision
hereof, the restrictions relating to assays described in Section 3 above do not
apply to, and shall not restrict, on a product-by-product basis, the
commercialization of an Existing Competing Product (as defined below) acquired
as part of an acquisition of a third party or business by Applera or any
Affiliate, nor shall any such provision prohibit an acquirer of Applera from
continuing to commercialize an Existing Competing Product following its
acquisition of Applera.

 

(b)                                          Definition of Existing Competing
Product.  For purposes of this Agreement, “Existing
Competing Product” means a product that (i) a third party has: (w) commercialized
on or before the date of acquisition, or (x) submitted to a regulatory
authority for approval or clearance on or before the date of acquisition, or (y) initiated
clinical trials in connection with regulatory submission on or before the date
of acquisition, or (z) Quality System Regulation documentation showing
that such product was in development before May 1, 2008 and (ii) is a
CE Assay, Maui Assay, or Real-Time Assay.

 

(c)           Use of Applera Technology.  Notwithstanding any other
provision hereof, in the event Applera is acquired by a third party, and such
acquirer elects to produce a competing product that is not dependent on Applera
technology, it will be free from any restrictions on such competing product
under this Agreement.  For the avoidance
of doubt, the fact that an acquirer has obtained a license under rights from
Applera to make, have made, use and sell the competing product but that the
competing product is substantially the result of the design and development of the
acquirer, shall not be construed for purposes herein as being “dependent on
Applera technology.”

 

Section 3.10  Use and Restrictions of Confidential
Information, Know-How and Trade Secrets.

 

(a)           Any Information Known solely by one
Group prior to the Effective Date (“Sole Information”) will be owned solely by
the Party that is the successor to that Group (including by way of name change)
after the Effective Date.  Neither Party
shall be permitted to use or disclose Sole Information of the other Party, except
to the extent that such Sole Information (i) is or becomes generally
available to the public, (ii) is independently developed after the
Effective Date by the Party that did not Know such Information prior to the
Effective Date, or (iii) becomes available after the Effective Date to the
Party that did not Know such Information prior to the Effective Date on a
nonconfidential basis from a source other than the other Party, provided that
such source is not subject to a confidentiality agreement or other obligation
of confidentiality to the other Party or any other Person with respect to any
of such Information.  For purposes of
this Section 3.10(a), “Know” shall mean actual knowledge, as well as
Information in a Party’s possession in written, electronic or other tangible or
intangible forms, stored in any medium.

 

 

 

11

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

(b)           With respect to Information relating
to the Celera Business or the Applied Biosystems Business that is Known by both
Groups (“Joint Information”), Celera’s use of such Joint Information after the
Effective Date shall be limited to the HIVD Field.  However, Celera may use or disclose to third
parties for any purpose such Joint Information primarily generated by the
Celera Group using its resources prior to the Effective Date, except for those
assets and businesses that have been transferred to the Applied Biosystems
Group (including, by way of example, the assets transferred by Celera to the
Applied Biosystems Group related to the Celera Discovery System).  If the Joint Information relates to the
Applied Biosystems Business and was primarily generated by the Applied
Biosystems Group using its resources prior to the Effective Date, Celera may
not disclose such Joint Information without the approval of Applera.  For purposes of this Section 3.10(b),
Joint Information shall not include Information that (i) is or becomes
generally available to the public other than through any act in violation of
this Agreement by the Party seeking to use or disclose such Joint Information, (ii) is
independently developed after the Effective Date by the Party seeking to use or
disclose such Joint Information, or (iii) becomes available after the
Effective Date to the Party seeking to use or disclose such Joint Information
on a nonconfidential basis from a source other than the other Party, provided
that such source is not subject to a confidentiality agreement or other
obligation of confidentiality to the other Party or any other Person with
respect to any of such Information.

 

(c)           Applera shall not use or disclose
Information that specifically relates to FDA requirements for registration of
an instrument under the Kauai Project as of the Effective Date, that was
primarily generated by the Celera Group using its resources prior to the
Effective Date, and that is Known by both Groups (the “FDA Information”).  For purposes of this Section 3.10(c),
FDA Information shall not include Information that (i) is or becomes
generally available to the public other than through any act of Applera in
violation of this Agreement, (ii) is independently developed by Applera
after the Effective Date, or (iii) becomes available to Applera after the
Effective Date on a nonconfidential basis from a source other than Celera,
provided that such source is not subject to a confidentiality agreement or
other obligation of confidentiality to Celera or any other Person with respect
to any of such FDA Information.  In
addition, Applera shall not use or disclose: (i) Celera’s Quality Manual
and associated operating procedures for conformance to FDA’s Quality System
Regulation; (ii) strategic plans of the Celera Business as presented by
Celera’s executive management to Applera’s executive management; or (iii) Celera’s
diagnostic product designs and batch records. 
In the event that Applera elects to seek FDA registration for an
instrument under the Maui Project, it shall make a good faith effort to avoid
using the Celera Group’s Kauai design and specifications required for FDA
compliance that is Known to the Applied Biosystems Group prior to the Effective
Date.  Notwithstanding its use of good
faith efforts, in the event Applera should inadvertently use any of such
Information specified in this Section 3.10(c), the Parties will discuss an
appropriate course of action for such inadvertent use, prior to subjecting the
matter to the Dispute Resolution Procedures set forth in Article V of this
Agreement.

 

 

 

12

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

ARTICLE IV

RELATIONSHIP TO
OTHER DOCUMENTS

 

If there is
any conflict or inconsistency between the terms and conditions of this
Agreement and the Separation Agreement, the provisions of this Agreement shall
control solely with respect to the rights and obligations of the Parties set
forth herein.

 

ARTICLE V

DISPUTE RESOLUTION

 

If a dispute
arises between the Parties with respect to the terms and conditions of this
Agreement, or any subject matter governed by this Agreement, the Parties agree
to use and follow the dispute resolution procedures set forth in Article XIII
of the Separation Agreement to resolve any such dispute.

 

ARTICLE VI

INDEMNIFICATION

 

Each Party shall indemnify, defend and hold
harmless the other Party, against and in respect of any and all Indemnifiable
Losses that result from, relate to or arise out of this Agreement, to the
extent and in the manner set forth in Article XI of the Separation
Agreement, except to the extent that any such Indemnifiable Losses arise out of
or result from the gross negligence or willful misconduct of such other Party.

 

ARTICLE VII

FORCE MAJEURE

 

No Party shall be in default of this
Agreement to the extent that any delay or failure in the performance of its
obligations under this Agreement results from any cause beyond its reasonable
control and without its fault or negligence, such as acts of God, acts of civil
or military authority, embargoes, epidemics, war, riots, insurrections, fires,
explosions, earthquakes, floods, unusually severe weather conditions, power
failures, communication failures including internet disruptions, equipment
failures, labor problems or unavailability of parts.  In the event of any such excused delay, the
time for performance shall be extended for a period equal to the time lost by
reason of the delay.

 

ARTICLE VIII

TERMINATION

 

Section 8.1          Termination.  This Agreement may be terminated at any time
by the mutual written consent of the Parties.

 

Section 8.2          Termination
for Default.  In the event: (i) either
Party shall default, in any material respect, in the due performance or
observance by it of any of the other terms, 

 

 

13

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

covenants or
agreements contained in this Agreement or (ii) either Party shall become
or be adjudicated insolvent and/or bankrupt, or a receiver or trustee shall be
appointed for either Party or its property or a petition for reorganization or
arrangement under any bankruptcy or insolvency law shall be approved, or either
Party shall file a voluntary petition in bankruptcy or shall consent to the
appointment of a receiver or trustee, the non-defaulting Party shall have the
right, at its sole discretion, (A) in the case of a default under clause
(ii), to immediately terminate this Agreement, and (B) in the case of a
default under clause (i), to terminate this Agreement if the defaulting Party
has failed to (x) cure the default within thirty (30) days of written
notice of default or if the default (except for defaults as a result of failure
to make payment) is such that it will take more than thirty (30) days to cure,
within an extended time period which shall be not longer than what is
reasonably necessary to effect performance or compliance or (y) diligently
pursue the curing of the default.

 

Section 8.3          Return
or Destruction of Material.  Upon
termination of this Agreement, each of Applera and Celera will, and will cause
their respective Subsidiaries to, return or destroy any and all material and
property of a proprietary nature involving the other Party and its
Subsidiaries, in its possession or control, within thirty (30) days after the
termination of this Agreement. 
Notwithstanding anything to the contrary contained in this Agreement,
upon the termination or expiration of this Agreement, Celera shall no longer be
entitled to, and shall cease all access to Applera’s information, data, systems
and other assets that are not Celera Group Assets and Applera shall no longer
be entitled to, and shall cease all access to Celera’s information, data,
systems and other assets that are not Applied Biosystems Group Assets.

 

Section 8.4             Effect of Termination.  The provisions of Section 3.10 and
Articles IV, V, VI, VII, VIII and X shall survive the termination or expiration
of this Agreement.

ARTICLE IX

OTHER
REPRESENTATIONS, WARRANTIES AND COVENANTS

 

Section 9.1             Compliance with Laws.  Each Party shall comply, at its own expense,
with the provisions of all laws applicable to the performance of its
obligations under this Agreement.

 

Section 9.2             Books and Records.  Each Party or its Affiliates will maintain
books and records substantially similar to those maintained prior to the date
hereof pertaining to that portion of the Applera businesses attributable to
such Party.  Each Party or its Affiliates
will provide the other Party with access to such books and records in
accordance with the provisions of Section 9.2 of the Separation
Agreement.  All such information shall be
subject to the terms of the confidentiality provisions set forth in Section 9.6
of the Separation Agreement.

 

Section 9.3             No Other Representations or
Warranties.  EXCEPT FOR THE
REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER
PARTY NOR ANY OTHER PERSON MAKES ANY OTHER EXPRESS OR IMPLIED REPRESENTATION OR
WARRANTY ON BEHALF OF EITHER PARTY WITH RESPECT TO THE APPLERA BUSINESSES, AT
LAW OR IN EQUITY, 

 

 

14

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

INCLUDING,
WITHOUT LIMITATION, WITH RESPECT TO MERCHANTABILITY OR FITNESS FOR ANY
PARTICULAR PURPOSE, AND ANY SUCH OTHER REPRESENTATIONS OR WARRANTIES ARE HEREBY
EXPRESSLY DISCLAIMED.

 

ARTICLE X

MISCELLANEOUS

 

Section 10.1           Relationship of the Parties.  The Parties declare and agree that each Party
is engaged in a business that is independent from that of the other Party and
each Party shall perform its obligations as an independent contractor.  It is expressly understood and agreed that
Celera and Applera are not partners or joint venturers, and nothing contained
herein is intended to create an agency relationship or a partnership or joint
venture.  Neither Applera nor any of its
Affiliates is an agent of Celera or any of its Affiliates and has no authority
to represent Celera or any of its Affiliates as to any matters, except as
provided in Section 3.2(c) of this Agreement or in writing by Celera
from time to time.  Neither Celera nor
any of its Affiliates is an agent of Applera or any of its Affiliates and has
no authority to represent Applera or any of its Affiliates as to any matters,
except as authorized in this Agreement or in writing by Applera from time to
time.

 

Section 10.2           Employees of the Parties.  Applera shall be solely responsible for
payment of compensation to its employees and for any injury to them in the
course of their employment.  Applera
shall assume full responsibility for payment of all federal, state and local
taxes or contributions imposed or required under unemployment insurance, social
security and income tax laws with respect to such persons.  Celera shall be solely responsible for
payment of compensation to its employees and for any injury to them in the
course of their employment.  Celera shall
assume full responsibility for payment of all federal, state and local taxes or
contributions imposed or required under unemployment insurance, social security
and income tax laws with respect to such persons.

 

Section 10.3        Notices.  All notices, requests, demands, waivers and
communications required or permitted to be given under this Agreement shall be
in writing (which shall include notice by telecopy or like transmission) and
shall be deemed given (i) on the day delivered (or if that day is not a Business
Day, on the first following Business Day) when (x) delivered personally
against receipt or (y) sent by overnight courier, (ii) on the day
when transmittal confirmation is received if sent by telecopy (or if that day
is not a Business Day, on the first following Business Day) and (iii) on
the third Business Day after mailed by certified or registered first-class mail
to the Parties at the following addresses (or to such other addresses as a
Party may have specified by notice given to the other Party hereto pursuant to
this provision):

 

	
  If to
  Applera, to:

  
	
   

  	
   

  
	
   

  	
  Applera Corporation

  
	
   

  	
  301 Merritt 7

  
	
   

  	
  Norwalk, Connecticut 06851

  
	
   

  	
  Attention: General Counsel

  
	
   

  	
  Facsimile: (203) 840-2902

  

 

 

 

15

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

	
  With a copy to:

  
	
   

  	
   

  
	
   

  	
  Applied Biosystems

  
	
   

  	
  850 Lincoln Centre Drive

  
	
   

  	
  Foster City, California 94404

  
	
   

  	
  Attention: Vice President Intellectual
  Property

  
	
   

  	
  Facsimile: (650) 638-6677

  
	
   

  	
   

  
	
  If to
  Celera, to:

  
	
   

  	
   

  
	
   

  	
  Celera Corporation

  
	
   

  	
  1401 Harbor Bay Parkway

  
	
   

  	
  Alameda, California 94502

  
	
   

  	
  Attention: President

  
	
   

  	
  Facsimile: (510) 749-4267

  

 

Section 10.4        Governing
Law.  This Agreement shall be
governed by, and construed in accordance with, the laws of Delaware, without
reference to choice of law principles, including matters of construction,
validity and performance.

 

Section 10.5        Parties
in Interest; Assignment; Successors. 
Neither this Agreement nor any of the rights, interests or obligations
hereunder shall be assigned by any of the Parties hereto (other than to a
successor of either Party by way of merger, consolidation, sale of all or
substantially all of such Party’s assets or similar transaction) without the
prior written consent of the other Parties. 
Subject to the preceding sentence, this Agreement shall inure to the
benefit of and be binding upon Celera and Applera and their respective
Subsidiaries, successors and permitted assigns. 
Nothing in this Agreement, express or implied, is intended to confer
upon any other Person any rights or remedies under or by reason of this
Agreement.

 

Section 10.6        Entire
Agreement.  This Agreement, including
the schedules, appendices, certificates, instruments and agreements delivered
pursuant hereto, contain the entire understanding of the Parties hereto and
thereto with respect to the subject matter contained herein and therein, and
supersede and cancel all prior agreements, negotiations, correspondence,
undertakings and communications of the Parties, oral or written, respecting
such subject matter.

 

Section 10.7        Exhibits.  All exhibits referenced in this Agreement and
attached hereto are incorporated into this Agreement by reference and made a
part hereof.

 

Section 10.8        Waivers
of Default.  Waiver by any Party of
any default by any other Party of any provision of this Agreement (a) shall
be effective only if in writing; and (b) if given, shall not be deemed a
waiver by the waiving Party of any subsequent or other default, nor shall it
prejudice the rights of the other Party.

 

Section 10.9           Amendments.  No provisions of this Agreement shall be
deemed amended, supplemented or modified by any Party, unless such amendment,
supplement or 

 

 

16

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

modification is in writing and signed by the authorized representative
of the Party against whom such waiver, amendment, supplement or modification is
sought to be enforced.

 

Section 10.10      Headings  The article, section and paragraph headings
contained in this Agreement are for reference purposes only and shall not
affect in any way the meaning or interpretation of this Agreement.  All references herein to “Articles” or
“Sections” shall be deemed to be references to Articles or Sections hereof
unless otherwise indicated.

 

Section 10.11      Severability;
Enforcement.  The invalidity of any
portion hereof shall not affect the validity, force or effect of the remaining
portions hereof.  If it is ever held that
any restriction hereunder is too broad to permit enforcement of such
restriction to its fullest extent, each Party agrees that a court of competent
jurisdiction may enforce such restriction to the maximum extent permitted by
law, and each Party hereby consents and agrees that such scope may be judicially
modified accordingly in any proceeding brought to enforce such restriction.

 

Section 10.12      No
Third-Party Beneficiaries.  Nothing
in this Agreement shall confer any rights upon any Person or entity other than
the Parties and their respective heirs, successors and permitted assigns.

 

Section 10.13         Remedies.  The Parties agree that money damages or other
remedy at law would not be a sufficient or adequate remedy for any breach or
violation of, or a default under, this Agreement by them and that in addition
to all other remedies available to them, each of them shall be entitled to the
fullest extent permitted by law to an injunction restraining such breach,
violation or default or threatened breach, violation or default and to any
other equitable relief, including specific performance, without bond or other
security being required.

 

Section 10.14         Expenses.  Except as otherwise provided in this
Agreement, the Parties shall bear their own expenses (including all time and
expenses of counsel, financial advisors, consultants, actuaries and independent
accountants) incurred in connection with this Agreement.

 

Section 10.15         Counterparts.  This Agreement may be executed in one or more
counterparts, which may be delivered by facsimile or scanned electronic copy in
pdf format, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

Section 10.16         No Set-Off.  The obligations under this Agreement shall
not be subject to set-off for non-performance or any monetary or non-monetary
claim by any Party or any of their respective Affiliates under any other
agreement between the Parties or any of their respective Affiliates.

 

Section 10.17         Confidentiality.  Disclosure and use of Confidential
Information by the Parties shall be governed by Section 9.6 of the
Separation Agreement and Section 3.10 of this Agreement.

 

Section 10.18         Facilities
and Systems Security.  If either
Party or its personnel shall be given access to the other Party’s facilities,
premises, equipment or systems, such Party 

 

 

 

17

 

 

shall comply with all such
other Party’s written security policies, procedures and requirements made
available by each Party to the other, and shall not tamper with, compromise, or
circumvent any security or audit measures employed by such other Party.  Each Party shall use its reasonable best
efforts to ensure that only those of its personnel who are specifically
authorized to have access to the facilities, premises, equipment or systems of
the other Party gain such access, and to prevent unauthorized access, use,
destruction, alteration or loss in connection with such access.

 

[SIGNATURE PAGE FOLLOWS]

 

 

 

18

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

IN WITNESS
WHEREOF, the Parties hereto have executed and delivered this Agreement as of
the date first above written.

 

 

	
   

  	
  APPLERA CORPORATION

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
  Title:

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  CELERA CORPORATION

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
  Title:

  

 

 

Exhibit A

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

Definition of HIVD Field

 

Human
In Vitro Diagnostics Field.  The phrase “Human In Vitro Diagnostics Field”
shall mean the field of use comprising products, technologies, services and/or
processes for use in the measurement, observation or determination of
attributes, characteristics, diseases, traits or other conditions of a human
being:

 

	
  ·

  	
   

  	
  for the
  medical management of a human being; and/or

  
	
  ·

  	
   

  	
  for quality
  control or testing of human blood or tissue for transfusion or blood banking,
  bone marrow transplantation or banking, or tissue typing for transplantation
  (where “banking” refers to human samples that are stored in anticipation of
  future implantation into the donor or transplantation into another human
  recipient).

  

 

Examples of activities in the HIVD Field:

 

	
  ·

  	
   

  	
  Development, manufacture, or sale of anything labeled for in vitro
  diagnostic use or any testing products labeled for investigational
  use;

  
	
  ·

  	
   

  	
  Development, manufacture, or sale of products designated as Analyte
  Specific Reagents (ASRs) by FDA or corresponding reagent products in foreign
  regulatory jurisdictions and general purpose reagents (GPRs) that are
  specifically sold for use with ASRs or such reagent products;

  
	
  ·

  	
   

  	
  Development or sale of software products for the interpretation of
  data to provide an HIVD clinical test result;

  
	
  ·

  	
   

  	
  Development, manufacture, or sale of products that convey
  amplification, sequencing, or other patent rights in the HIVD Field, or
  products that are designated specifically for use with products that convey
  amplification, sequencing, or other patent rights in the HIVD Field;

  
	
  ·

  	
   

  	
  Genetic testing for sample tracking in a clinical laboratory;

  
	
  ·

  	
   

  	
  Sale of any in vitro testing
  products regulated by the FDA, including products claimed to be produced
  under Quality System Regulation to be sold to IVD companies or clinical
  testing laboratories;

  
	
  ·

  	
   

  	
  In- and out-licensing or other transfer of patents, technology, or
  know-how for HIVD use (including any accompanying contract manufacture of
  custom reagents for specific diagnostic customers’ homebrew testing, whether
  or not the reagents are produced under Quality System Regulation);

  
	
  ·

  	
   

  	
  Development, manufacture, or sale of, or providing service and
  support for, systems (reagents, components and/or instruments) developed and
  manufactured for HIVD use or developed specifically for use with ASRs (or
  their counterparts outside the US); and

  
	
  ·

  	
   

  	
  Provision of
  HIVD testing services.

  

 

Examples of
activities not in the HIVD Field:

 

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

	
  ·

  	
   

  	
  Development,
  manufacture, or sale of products or services for basic and applied research,
  including clinical research where the medical management of a patient is not
  involved, unless the product or service is regulated as an in vitro
  diagnostic test or ASR by the FDA or its foreign counterparts;

  
	
  ·

  	
   

  	
  Development,
  manufacture, or sale of products or services for quality assurance and
  quality control, including testing to determine conformance with
  specifications, purity and batch-to-batch consistency, but excluding human
  plasma or tissue-derived samples for the pharmaceutical industry;

  
	
  ·

  	
   

  	
  Testing of
  environmental samples, including the detection of organisms, where the
  medical management of a human is not involved;

  
	
  ·

  	
   

  	
  Identity
  testing applications for forensic purposes or determination of paternity,
  excluding genotyping or other identification testing for medical management
  of a human being or sample tracking in a clinical laboratory;

  
	
  ·

  	
   

  	
  In vitro  diagnostic
  testing of non-human (plant or animal) samples, including animal breeding,
  pedigree determination, or gender determination;

  
	
  ·

  	
   

  	
  Testing for
  the agricultural or food industries, including the identification of
  genetically modified organisms (GMOs) for these industries;

  
	
  ·

  	
   

  	
  Sale or
  service of general purpose (“open”) instrument systems or general purpose
  reagents, including enzymes; unless such GPRs are specifically sold for use
  with ASRs or other products regulated by the FDA or its foreign counterparts;

  
	
  ·

  	
   

  	
  Sale of
  non-exclusive information products and services not regulated by FDA (such as
  the Celera Discovery System) to any customers, including those customers
  operating in the HIVD Field;

  
	
  ·

  	
   

  	
  Sale of
  anything labeled for therapeutic or prophylactic use;

  
	
  ·

  	
   

  	
  Sale of
  products or services that convey therapeutic or research patent rights;

  
	
  ·

  	
   

  	
  In- and out-
  licensing or other transfer of patents, technology or know-how for use in the
  therapeutic, research, or applied fields;

  
	
  ·

  	
   

  	
  Embryonic
  stem cell and recombinant cell characterization, testing, and quality control
  applications; and

  
	
  ·

  	
   

  	
  Epidemiology
  testing (the screening or testing of groups of people or populations for the
  study of the patterns, causes, or control of disease in groups of people) and
  biosecurity testing (the detection of biological or chemical agents,
  pathogens, microorganisms or other infectious agents in the environment,
  agriculture, food or water), where the medical management of a human is not
  involved.

  

 

 

Exhibit B

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

Specified Country List

 

Africa

 

	
  ·

  	
  Algeria

  	
  ·

  	
  Guinea

  	
  ·

  	
  Senegal

  
	
  ·

  	
  Angola

  	
  ·

  	
  Ivory Coast

  	
  ·

  	
  Seychelles

  
	
  ·

  	
  Benin

  	
  ·

  	
  Kenya

  	
  ·

  	
  Sierra Leone

  
	
  ·

  	
  Botswana

  	
  ·

  	
  Lesotho

  	
  ·

  	
  Somalia

  
	
  ·

  	
  Burkina Faso

  	
  ·

  	
  Liberia

  	
  ·

  	
  South Africa

  
	
  ·

  	
  Burundi

  	
  ·

  	
  Libya

  	
  ·

  	
  Sudan

  
	
  ·

  	
  Cameroon

  	
  ·

  	
  Madagascar

  	
  ·

  	
  Swaziland

  
	
  ·

  	
  Cape Verde

  	
  ·

  	
  Malawi

  	
  ·

  	
  Tanzania

  
	
  ·

  	
  Central African Republic

  	
  ·

  	
  Mali

  	
  ·

  	
  Togo

  
	
  ·

  	
  Chad

  	
  ·

  	
  Mauritania

  	
  ·

  	
  Tunisia

  
	
  ·

  	
  Comoros

  	
  ·

  	
  Mauritius

  	
  ·

  	
  Uganda

  
	
  ·

  	
  Congo

  	
  ·

  	
  Mayotte (France)

  	
  ·

  	
  Western Sahara

  
	
  ·

  	
  Dem. Republic of Congo (Zaire)

  	
  ·

  	
  Morocco

  	
  ·

  	
  Zambia

  
	
  ·

  	
  Djibouti

  	
  ·

  	
  Mozambique

  	
  ·

  	
  Zanzibar

  
	
  ·

  	
  Egypt

  	
  ·

  	
  Namibia

  	
  ·

  	
  Zimbabwe

  
	
  ·

  	
  Equatorial Guinea

  	
  ·

  	
  Niger

  	
   

  	
   

  
	
  ·

  	
  Eritrea

  	
  ·

  	
  Nigeria

  	
   

  	
   

  
	
  ·

  	
  Ethiopia

  	
  ·

  	
  Réunion

  	
   

  	
   

  
	
  ·

  	
  Gabon

  	
  ·

  	
  Rwanda

  	
   

  	
   

  
	
  ·

  	
  Gambia

  	
  ·

  	
  Saint Helena (UK)

  	
   

  	
   

  
	
  ·

  	
  Ghana

  	
  ·

  	
  Sao Tome and Principe

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Asia

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Afghanistan

  	
  ·

  	
  Hong Kong

  	
  ·

  	
  North Korea

  
	
  ·

  	
  Bangladesh

  	
  ·

  	
  India

  	
  ·

  	
  Oman

  
	
  ·

  	
  Bhutan

  	
  ·

  	
  Indonesia

  	
  ·

  	
  Pakistan

  
	
  ·

  	
  Brit. Ind. Ocean Territory

  	
  ·

  	
  Japan

  	
  ·

  	
  Philippines

  
	
  ·

  	
  Brunei

  	
  ·

  	
  Laos

  	
  ·

  	
  Singapore

  
	
  ·

  	
  Cambodia

  	
  ·

  	
  Macau

  	
  ·

  	
  South Korea

  
	
  ·

  	
  China

  	
  ·

  	
  Malaysia

  	
  ·

  	
  Sri Lanka

  
	
  ·

  	
  Christmas Island

  	
  ·

  	
  Maldives

  	
  ·

  	
  Taiwan

  
	
  ·

  	
  Cocos Islands

  	
  ·

  	
  Mongolia

  	
  ·

  	
  Thailand

  
	
  ·

  	
  Cyprus

  	
  ·

  	
  Myanmar

  	
  ·

  	
  Vietnam

  
	
  ·

  	
  East Timor

  	
  ·

  	
  Nepal

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Middle East

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Bahrain

  	
  ·

  	
  Lebanon

  	
  ·

  	
  West Bank

  
	
  ·

  	
  Gaza Strip

  	
  ·

  	
  Qatar

  	
  ·

  	
  Yemen

  
	
  ·

  	
  Iran

  	
  ·

  	
  Saudi Arabia

  	
   

  	
   

  
	
  ·

  	
  Iraq

  	
  ·

  	
  Syria

  	
   

  	
   

  
	
  ·

  	
  Israel

  	
  ·

  	
  Tunisia

  	
   

  	
   

  
	
  ·

  	
  Jordan

  	
  ·

  	
  Turkey

  	
   

  	
   

  
	
  ·

  	
  Kuwait

  	
  ·

  	
  United Arab Emirates

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  South America

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Argentina

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Bolivia

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Brazil

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Chile

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Colombia

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Ecuador

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Falkland Islands (UK)

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  French Guiana (France)

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Guyana

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Paraguay

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Peru

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Suriname

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Uruguay

  	
   

  	
   

  	
   

  	
   

  
	
  ·

  	
  Venezuela

  	
   

  	
   

  	
   

  	
   

  

 

 

Exhibit C

 

	
   

  	
  Confidential Treatment Requested

  
	
   

  	
  By Celera Corporation

  

 

Forensics and Applied Markets

 

	
  ·

  	
   

  	
  Basic or applied research within academic,
  government, biotech, or pharmaceutical institutions;

  
	
  ·

  	
   

  	
  Quality assurance and quality control,
  including testing to determine conformance with specifications, purity, and
  batch-to-batch consistency within pharmaceutical institution’s Process
  Development, Manufacturing, or Quality Control departments;

  
	
  ·

  	
   

  	
  Testing of environmental samples, including
  the detection of organisms where the medical management of a human is not
  involved;

  
	
  ·

  	
   

  	
  Human identity testing applications for
  forensic purposes or determination of paternity;

  
	
  ·

  	
   

  	
  In vitro diagnostic testing of non-human (plant
  or animal) samples, including animal breeding, pathogen detection, pedigree
  determination, or gender determination;

  
	
  ·

  	
   

  	
  Testing for the agriculture or food
  industries, including pathogen detection and the identification of
  genetically modified organisms (GMOs) for these industries;

  
	
  ·

  	
   

  	
  Stem cell and recombinant cell
  characterization, testing, and quality control applications; and

  
	
  ·

  	
   

  	
  Epidemiology testing (the screening or testing
  of groups of people or populations for the study of patterns, causes, or control
  of disease in groups of people) and biosecurity testing (the detection of
  biological or chemical agents, pathogens, microorganisms or other infectious
  agents in the environment, agriculture, food or water), where the management
  of a human is not involved.Exhibit 10.4

 

[FORM OF
TAX MATTERS AGREEMENT]

 

TAX MATTERS AGREEMENT

 

by and among

 

APPLERA CORPORATION

 

AND ITS AFFILIATES,

 

and

 

CELERA CORPORATION

 

AND ITS AFFILIATES,

 

Dated

 

[DATE]

 

 

TAX MATTERS AGREEMENT

 

THIS
TAX MATTERS AGREEMENT (this “Agreement”) dated as of [date], by and among
Applera Corporation, a Delaware corporation (“Applera”), each Applera
Affiliate, Celera Corporation, a Delaware corporation (“Celera”), and each
Celera Affiliate (the “Parties”) is entered into in connection with the Split-Off.  Capitalized terms used in this Agreement are
defined herein.

 

W  I  T
N  E  S  S  E  T  H:

 

WHEREAS,
as of the date hereof, Applera and its direct and indirect domestic
subsidiaries are members of an Affiliated Group, of which Applera is the common
parent;

 

WHEREAS,
Applera, acting through its direct and indirect subsidiaries, currently
conducts a number of businesses, including (i) the Applera Business, and (ii) the
Celera Business;

 

WHEREAS,
the Board of Directors of Applera has determined that it is appropriate,
desirable and in the best interests of Applera and its stockholders to separate
Applera into two separate, independent and publicly traded companies, (i) one
comprising the Celera Business, which shall be owned and conducted, directly or
indirectly, by Celera, and (ii) one comprising the Applera Business which
shall continue to be owned and conducted, directly or indirectly, by Applera;

 

WHEREAS,
in order to effect such separation, (i) Applera will contribute to the
capital of Celera the assets of the Celera Business, including the stock of
Berkeley Heart Laboratories (“BHL”), Axys Pharmaceuticals, Inc., PE AgGen, Inc.,
GenScope, Inc. and Paracel, Inc.; and have Celera assume liabilities
of the Celera Business (together, the “Contribution”) and (ii) all of the
stock of Celera will be exchanged on a one-for-one basis for all of the
outstanding Applera – CRA Tracking Stock (the “Exchange” and together with the “Contribution,”
the “Split-Off”).

 

WHEREAS,
Applera and Celera have determined that it is necessary and desirable, as part
of the Split-Off, to allocate, transfer, retain or assign to the Celera Group,
the Celera Group Assets and Celera Group Liabilities, and to allocate,
transfer, retain or assign to the Applera Group, the Applied Biosystems Group
Assets and Applied Biosystems Group Liabilities;

 

WHEREAS,
it is the intention of the Parties that the Split-Off qualify as a
reorganization within the meaning of sections 368(a)(1)(D) and 355 of the
Code and this Agreement is hereby adopted as a plan of reorganization within
the meaning of section 368 of the Code; and

 

WHEREAS,
in contemplation of the Split-Off, pursuant to which the Celera Group will
cease to be members of the Affiliated Group of which Applera is the parent, the
Parties have determined to enter into this Agreement, setting forth their
agreement with respect to certain tax matters.

 

2

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements contained
herein, the Parties hereby agree as follows:

 

Section 1.              Definitions.

 

“Affiliated Group” means an affiliated group of corporations within the meaning of
section 1504(a)(1) of the Code that files a consolidated return for United
States federal Income Tax purposes.

 

“After Tax Amount” means any additional amount necessary to reflect the hypothetical Tax
consequences of the receipt or accrual of any payment required to be made under
this Agreement (including  payment
of an additional amount or amounts hereunder and the effect of the deductions
available for interest paid or accrued and for Taxes such as state and local
Income Taxes), determined by using the highest applicable statutory corporate
Income Tax rate (or rates, in the case of an item that affects more than one
Tax) for the relevant taxable period (or portion thereof).

 

“Agreement” shall have the meaning set forth in the preamble hereto.

 

“Applera” shall have the meaning set forth in the
preamble hereto.

 

“Applera Affiliate” means any corporation or other entity directly or indirectly “controlled”
by Applera where “control” means the ownership of fifty percent (50%) of the
ownership interests of such corporation or other entity (by vote or value) or
the possession, directly or indirectly, of the power to direct or cause the
direction of the management or policies of such corporation or other entity,
but at all times excluding Celera and all Celera Affiliates.

 

“Applera Business” means all of the businesses and operations conducted by Applera and
the Applera Affiliates, excluding the Celera Business at any time, whether
prior to, or after the Split-Off Date.

 

“Applera  Group”
means the Affiliated Group, or similar group of entities as defined under
corresponding provisions of the laws of other jurisdictions, of which Applera
is the common parent corporation, and any corporation or other entity which may
be, may have been or may become a member of such group from time to time, but
excluding any member of the Celera Group.

 

“Applera-CRA Tracking Stock” means the Applera Corporation-Celera Group common stock.

 

“Applera Sharing Percentage” means as of the close of business on the first trading day after the
Split-Off Date, the percentage of Applera’s market capitalization as compared
to the combined market capitalization of Applera and Celera.

 

3

 

“Applied Biosystems Group Assets” shall mean the assets of Applera after the
Split-Off Date, as determined under the Separation Agreement by and among the
Parties.

 

“Applied Biosystems Group Liabilities” shall mean the liabilities of Applera after
the Split-Off Date, as determined under the Separation Agreement by and among
the Parties.

 

“Audit” means any audit, assessment of Taxes, other examination by any Taxing
Authority, proceeding, or appeal of such a proceeding relating to Taxes,
whether administrative or judicial, including proceedings relating to competent
authority determinations.

 

“BHL”
shall have the meaning set forth in the preamble hereto.

 

“BHL Affiliates” means any corporation or other entity
directly or indirectly “controlled” by BHL at the time in question, where “control”
means the ownership of fifty percent (50%) of the ownership interests of such
corporation or other entity (by vote or value) or the possession, directly or
indirectly, of the power to direct or cause the direction of the management or
policies of such corporation or other entity.

 

“Big Dye Agreement” means the supply agreement among Applera and Celera for Big Dye
Terminators.

 

“Carryback Period” shall have the meaning set forth in Section 3.05.

 

“Celera” shall have the meaning set forth in the preamble hereto.

 

“Celera Affiliate” means any corporation or other entity directly or indirectly “controlled”
by Celera at the time in question, where “control” means the ownership of fifty
percent (50%) of the ownership interests of such corporation or other entity
(by vote or value) or the possession, directly or indirectly, of the power to
direct or cause the direction of the management or policies of such corporation
or other entity.

 

“Celera Group Assets” shall mean the assets of Celera after the Split-Off Date, as
determined under the Separation Agreement by and among the Parties.

 

“Celera Business” means the business and operations conducted by Celera and the Celera
Affiliates as such business and operations will continue after the Split-Off
Date.

 

“Celera Business Records” shall have the meaning set forth in Section 9.02(b).

 

“Celera Group” means the Affiliated Group, or similar group of entities as defined under
corresponding provisions of the laws of other jurisdictions, of which Celera
will be the common parent corporation immediately after the Split-Off and
including any corporation or other entity which may become a member of such
group from time to time.

 

“Celera Group Liabilities” shall mean the liabilities of Celera after the Split-Off Date, as
determined under the Separation Agreement by and among the Parties.

 

4

 

“Celera Separate Tax Amount” shall mean with
respect to any Tax Return, the amount of Taxes attributable to a Post-Split-Off Period that Celera and each
Celera Affiliate would have incurred if they had filed a consolidated return,
combined return or a separate return, as the case may be, separate from the
members of the Applera Group, for the relevant Tax period, and such amount
shall be computed by Applera in a manner consistent with (i) general Tax
accounting principles, (ii) the Code and the Treasury regulations
promulgated thereunder, and (iii) past practice.

 

“Celera Sharing Percentage” means as of the close of business
on the first trading day after the Split-Off Date, the percentage of Celera’s
market capitalization as compared to the combined market capitalization of
Applera and Celera.

 

“Code”
means the Internal Revenue Code of 1986, as amended.

 

“Combined Return” means any Tax Return, other than with respect to United States federal
Income Taxes, filed on a consolidated, combined (including nexus combination,
worldwide combination, domestic combination, line of business combination or
any other form of combination) or unitary basis wherein Celera or one or more
Celera Affiliates join in the filing of such Tax Return (for any taxable period
or portion thereof) with Applera or one or more Applera Affiliates.

 

“Consolidated Return” means any Tax Return with respect to United
States federal Income Taxes filed on a consolidated basis wherein Celera or one
or more Celera Affiliates join in the filing of such Tax Return (for any
taxable period or portion thereof) with Applera or one or more Applera
Affiliates.

 

“Contribution”
shall have the meaning set forth in the recitals hereto.

 

“Contribution Taxes” shall mean any U.S. federal income tax imposed relating to the
Contribution, including as a result of the Parties entering into the IP Access
Agreements; provided, however, that Contribution Taxes shall not
include Taxes related to the Big Dye Agreement. 
For the avoidance of doubt, Contribution Taxes shall not include any
Exchange Taxes.

 

“Estimated Tax Installment Date” means, with respect to United States federal
Income Taxes, the estimated Tax installment due dates prescribed in section
6655(c) of the Code and, in the case of any other Tax, means any other
date on which an installment payment of an estimated amount of such Tax is
required to be made.

 

“Exchange” shall have the meaning set forth in the recitals hereto.

 

“Exchange Taxes” means any Taxes imposed on, or increase in Taxes incurred by, Applera
or any Applera Affiliate (without regard to whether such Taxes are offset or
reduced by any Tax Asset, Tax Item, or otherwise) resulting from, or arising in
connection with, the failure of the Exchange to qualify as a transaction in
which no income, gain or loss is recognized 

 

5

 

pursuant
to sections 355 and 368(a)(1)(D) of the Code (including any Tax resulting
from the application of section 355(d) or section 355(e) of the Code
to the Exchange) or corresponding provisions of the laws of any other jurisdictions.  Any Income Tax referred to in the immediately
preceding sentence shall be determined using the highest applicable statutory
corporate Income Tax rate for the relevant taxable period (or portion thereof).

 

“Filing Party” shall have the meaning set forth in Section 8.01.

 

“Final Determination” means the final resolution of liability for
any Tax for any taxable period, by or as a result of (i) a final and
unappealable decision, judgment, decree or other order by any court of
competent jurisdiction; (ii) a final settlement with the IRS, a closing
agreement or accepted offer in compromise under section 7121 or section 7122 of
the Code, or a comparable agreement under the laws of other jurisdictions,
which resolves the entire Tax liability for any taxable period; (iii) any
allowance of a refund or credit in respect of an overpayment of Tax, but only
after the expiration of all periods during which such refund may be recovered
by the jurisdiction imposing the Tax; or (iv) any other final disposition,
including by reason of the expiration of the applicable statute of limitations.

 

“Income Tax” means any federal, state, local or foreign Tax determined (in whole or
in part) by reference to net income, net worth, gross receipts or capital, or
any such Taxes imposed in lieu of such a Tax. 
For the avoidance of doubt, the term “Income Tax” includes any franchise
Tax, net worth, gross receipts, capital or any such Taxes imposed in lieu of
such a Tax.

 

“Income Tax Return” means any Tax Return relating to any Income Tax.

 

“ IP Access Agreements” means the agreements entered into by the Parties to license IP and
supply goods to the other Party for a period of time after the Split-Off.

 

“IRS”
means the United States Internal Revenue Service or any successor thereto, including
its agents, representatives, and attorneys.

 

“Joint Responsibility Item” means any Tax Item for which the non-Filing
Party’s responsibility under this Agreement could exceed one hundred thousand
dollars ($100,000), but not a Sole Responsibility Item.

 

“Non-Income Tax Return” means any Tax Return relating to any Tax
other than an Income Tax.

 

“Officer’s Certificate” means a letter executed by an officer of
Applera or Celera and provided to Tax Counsel as a condition for the completion
of a Tax Opinion or Supplemental Tax Opinion.

 

“Owed Party” shall have the meaning set forth in Section 7.05.

 

“Owing Party” shall have the meaning set forth in Section 7.05.

 

6

 

“Parties” shall have the meaning set forth in the preamble hereto.

 

“Payment Period” shall have the meaning set forth in Section 7.05(e).

 

“Post-Split-Off Period” means any taxable period (or portion
thereof) beginning after the Split-Off Date.

 

“Pre-Split-Off Period” means any taxable period (or portion
thereof) ending on or before the Split-Off Date.

 

“Proposed Merger” means the proposed merger of Applera with and into Invitrogen
Corporation or an entity wholly owned by Invitrogen Corporation.

 

“Ruling”  means
any private letter ruling issued by the IRS in connection with the Split-Off in
response to a request for such a private letter ruling filed by Applera (or any
Applera Affiliate).

 

“Ruling Documents” means (i) the request for a Ruling filed with the IRS, together
with any supplemental filings or other materials subsequently submitted on
behalf of Applera, the Applera Affiliates and Applera’s shareholders to the
IRS, the appendices and exhibits thereto, and any Ruling issued by the IRS to
Applera (or any Applera Affiliate) in connection with the Split-Off and (ii) any
similar filings submitted to, or rulings issued by, any other Taxing Authority
in connection with the Split-Off.

 

“Separation Agreement” means the separation agreement by and between Applera and Celera.

 

“Sole Responsibility Item” means any Tax Item for which the non-Filing
Party has the entire economic liability under this Agreement.

 

“Split-Off”
shall have the meaning set forth in the recitals hereto.

 

“Split-Off Date” means the close of business on the date which the Split-Off is effected.

 

“Straddle Period” shall mean any taxable period that begins on or before and ends after
the Split-Off Date.

 

“Supplemental Tax Opinion”  shall have the meaning set forth in Section 4.02(d).

 

“Tax Asset” means any Tax Item that has accrued for Tax purposes, but has not been
realized during the taxable period in which it has accrued, and that could
reduce a Tax in another taxable period, including a net operating loss, net
capital loss, research and development tax credit, investment tax credit, foreign
tax credit, charitable deduction or credit related to alternative minimum tax
or any other Tax credit.

 

7

 

“Tax Benefit” means a reduction in the Tax liability (or increase in refund or
credit or any item of deduction or expense) of a taxpayer (or of the Affiliated
Group, or similar group of entities as defined under corresponding provisions
of the laws of any other jurisdiction, of which it is a member) for any taxable
period.  Except as otherwise provided in
this Agreement, a Tax Benefit shall be deemed to have been realized or received
from a Tax Item in a taxable period only if and to the extent that the Tax
liability of the taxpayer (or of the Affiliated Group, or similar group of
entities as defined under corresponding provisions of the laws of any other
jurisdiction, of which it is a member) for such period, after taking into
account the effect of the Tax Item on the Tax liability of such taxpayer (or of
the Affiliated Group, or similar group of entities as defined under
corresponding provisions of the laws of any other jurisdiction, of which it is
a member) in the current period and all prior periods, is less than it would
have been had such Tax liability been determined without regard to such Tax Item.

 

“Tax Counsel” means a nationally recognized law firm selected by Applera to provide
a Tax Opinion.

 

“Tax Detriment” means an increase in the Tax liability (or reduction in refund or
credit or any item of deduction or expense) of a taxpayer (or of the Affiliated
Group, or similar group of entities as defined under corresponding provisions
of the laws of any other jurisdiction, of which it is a member) for any taxable
period.  Except as otherwise provided in
this Agreement, a Tax Detriment shall be deemed to have been realized or
incurred from a Tax Item in a taxable period only if and to the extent that the
Tax liability of the taxpayer (or of the Affiliated Group, or similar group of
entities as defined under corresponding provisions of the laws of any other
jurisdiction, of which it is a member) for such period, after taking into
account the effect of the Tax Item on the Tax liability of such taxpayer (or of
the Affiliated Group, or similar group of entities as defined under
corresponding provisions of the laws of any other jurisdiction, of which it is
a member) in the current period and all prior periods, is more than it would
have been had such Tax liability been determined without regard to such Tax
Item.

 

“Tax Item” means any item of income, gain, loss, deduction, expense or credit, or
other attribute that may have the effect of increasing or decreasing any Tax.

 

“Tax Opinion” means an opinion issued by Tax Counsel as one of the conditions to
completing the Split-Off addressing certain United States federal Income Tax
consequences of the Split-Off under section 355 of the Code.

 

“Tax Return” means any return, report, certificate, form or similar statement or
document (including any related or supporting information or schedule attached
thereto and any information return, amended tax return, claim for refund or
declaration of estimated Tax) required to be supplied to, or filed with, a
Taxing Authority in connection with the determination, assessment or collection
of any Tax or the administration of any laws, regulations or administrative
requirements relating to any Tax.

 

“Taxes” means all federal, state, local or foreign taxes, charges, fees,
duties, levies, imposts, rates or other assessments, including income, gross
receipts, excise, property, sales, use, license, capital stock, transfer,
franchise, payroll, withholding, social security, value added or 

 

8

 

other
taxes, (including any interest, penalties or additions attributable thereto)
and a “Tax” shall mean any one of such Taxes.

 

“Taxing Authority” means any governmental authority or any subdivision, agency,
commission or authority thereof or any quasi-governmental or private body
having jurisdiction over the assessment, determination, collection or imposition
of any Tax (including the IRS).

 

Section 2.              Preparation and Filing of
Tax Returns.

 

2.01.        Applera’s Responsibility.  Subject to the other
applicable provisions of this Agreement, Applera shall have sole and exclusive
responsibility for the preparation and filing of:

 

(a) 
all Consolidated Returns and all Combined Returns for any taxable period;

 

(b) 
all Income Tax Returns (other than Consolidated Returns and Combined Returns)
with respect to Applera and/or any Applera Affiliate for any taxable period;

 

(c) all
Non-Income Tax Returns with respect to Applera, any Applera Affiliate, or the
Applera Business or any part thereof for any taxable period; and

 

(d) all
Non-Income Tax Returns with respect to Celera, any Celera Affiliate, or the
Celera Business or any part thereof, that are required to be filed (taking into
account any extension of time which has been requested or received) on or prior
to the Split-Off Date.

 

2.02.        Celera’s Responsibility.  Celera shall have sole and exclusive
responsibility for the preparation and filing of:

 

(a) 
all Income Tax Returns (other than Consolidated Returns and Combined Returns)
with respect to Celera and/or any Celera Affiliate for any taxable period that
are required to be filed after the Split-Off Date; and

 

(b) 
all Non-Income Tax Returns with respect to Celera, any Celera Affiliate, or the
Celera Business or any part thereof, that are required to be filed (taking into
account any extension of time which has been requested or received) after the
Split-Off Date.

 

2.03.        Agent.  Subject to the other applicable provisions of
this Agreement, Celera hereby irrevocably designates, and agrees to cause each
Celera Affiliate to so designate, Applera as its sole and exclusive agent and
attorney-in-fact to take such action (including execution of documents) as
Applera, in its sole discretion, may deem appropriate in any and all matters
(including Audits) relating to any Tax Return described in Section 2.01,
subject, however, to the joint control provisions and control by a non-Filing
Party provisions in Section 8.

 

2.04.        Manner of Tax Return Preparation.

 

(a) 
Unless otherwise required by a Taxing Authority, the Parties hereby agree to
prepare and file all Tax Returns, and to take all other actions, in a manner
consistent with (1) this 

 

9

 

Agreement,
(2) any Tax Opinion, (3) any Supplemental Tax Opinion, and (4) any
Ruling.  All Tax Returns shall be filed
on a timely basis (taking into account applicable extensions) by the Party responsible
for filing such returns under this Agreement.

 

(b) 
Subject to the other applicable provisions of this Agreement, Applera shall
have the exclusive right, in its sole discretion, with respect to any Tax
Return described in Section 2.01, to determine (1) the manner in
which such Tax Return shall be prepared and filed, including the elections,
method of accounting, positions, conventions and principles of taxation to be
used and the manner in which any Tax Item shall be reported, (2) whether
any extensions shall be requested, (3) the elections that will be made by
Applera, any Applera Affiliate, Celera, and/or any Celera Affiliate on such Tax
Return, (4) whether any amended Tax Returns shall be filed, (5) whether
any claims for refund shall be made, (6) whether any refunds shall be paid
by way of refund or credited against any liability for the related Tax, and (7) whether
to retain outside firms to prepare and/or review such Tax Returns.

 

Section 3.              Liability for Ordinary
Course Taxes.

 

3.01.        Applera’s Liability for Ordinary Course Taxes. 
Except as provided in Sections 4.01 and 4.03, Applera shall be liable
for the following Taxes, and shall be entitled to receive and retain all
refunds of:

 

(a) all
Taxes attributable to the Applera Group or the Applera Business, in each case
for any and all periods,

 

(b) except
for Taxes related to BHL and BHL Affiliates, all Taxes attributable to the
Celera Group, the Celera Group Assets or the Celera Business, in each case for
any and all Pre-Split-Off Periods,

 

(c) except
for Taxes related to BHL and BHL Affiliates, all Taxes for which the Celera
Group may be liable by virtue of any agreement or arrangement with respect to
Taxes (other than pursuant to this Agreement or any other agreements entered
into in connection with the Split-Off) entered into on or prior to the
Split-Off Date.

 

3.02.        Celera’s Liability for Ordinary Course Taxes.  
Except as provided in Sections 4.01 and 4.03, Celera and each Celera
Affiliate shall be jointly and severally liable for (i) all Taxes
attributable to any and all members of the Celera Group or the Celera Group
Assets or the Celera Business, in each case for any and all Post-Split-Off
Periods and (ii) all Taxes related to BHL and the BHL Affiliates for any
and all periods.

 

3.03.        Straddle Periods.  For purposes of Sections 3.01 and 3.02, in
the case of any Straddle Period, (i) property taxes and exemptions,
allowances or deductions that are calculated on an annualized basis shall be
apportioned between the Pre-Split-Off Period and the Post-Split-Off Period on a
daily pro-rata basis and (ii) all other Taxes shall be apportioned between
the Pre-Split-Off Period and the Post-Split-Off Period on a closing of the
books basis as of the close of business on the Split-Off Date.

 

10

 

3.04.  Refunds.  The amount or economic benefit of any
refunds, credits or offsets of Taxes relating to (i) Celera, the Celera
Group Assets or the Celera Business for a Pre-Split-Off Period shall be for the
account of Applera, (ii) Celera, the Celera Group Assets or the Celera
Business for a Post-Split-Off Period shall be for the account of Celera, and (iii) the
Applera Group, the Applied Biosystems Group Assets or the Applera Business
shall for the account of Applera.

 

3.05.  Carryback.  Notwithstanding Section 3.04, to the
extent permitted by law, the Celera Group shall elect to forego a carryback of
any net operating losses, capital losses, credits or other Tax benefits to a
taxable period, or portion thereof, ending on or before the Split-Off Date
unless Applera otherwise elects, in its sole discretion, to allow such
carryback.  To the extent that Celera is
required under law to carry back Tax Assets described in this section, Applera
agrees to pay to Celera the United States federal Income Tax Benefit from the
use in any Pre-Split-Off Period (the “Carryback Period”) of a carryback of any
such Tax Asset of the Celera Group from a Post-Split-Off Period (other than a
carryback of any Tax Asset attributable to Exchange Taxes for which the
liability is borne by Applera or any Applera Affiliate).  If subsequent to the payment by Applera to
Celera of the United States federal Income Tax Benefit of a carryback of a Tax
Asset of the Celera Group, there shall be a Final Determination which results
in a (1) change to the amount of the Tax Asset so carried back or (2) change
to the amount of such United States federal Income Tax Benefit, Celera shall
repay to Applera, or Applera shall repay to Celera, as the case may be, any
amount which would not have been payable to such other Party pursuant to this Section 3.05
had the amount of the benefit been determined in light of these events.  Nothing in this Section 3.05 shall
require Applera to file an amended Tax Return or claim for refund of United
States federal Income Taxes; provided, however, that Applera
shall use its commercially reasonable efforts to use any carryback of a Tax
Asset of the Celera Group that is carried back under this Section 3.05.

 

3.06.  Celera Tax Assets on Applera
Post-Split-Off Period Returns.  With
respect to any Post-Split-Off Period, to the extent that any Tax Assets
relating to the Celera Business attributable to Pre-Split-Off Periods remain
with the Applera Group after the Split-Off: (i) to the extent that the
Celera Group generates sufficient income or recognizes sufficient gains in a
given Tax period that the Celera Group would have been able to utilize such Tax
Assets (that were not already utilized by Applera pursuant to clause (ii)) on a
pro-forma basis, Applera shall compensate Celera for such utilizable amount on
a pro-forma basis, and (ii) to the extent that (A) Celera Group does
not generate sufficient income or recognize sufficient gains in such Tax period
and (B) Applera utilizes such Tax Assets on its Tax Returns for such Tax
Period, then Applera shall not be required to compensate Celera for Applera’s
utilization of such Tax Assets.  For the
avoidance of doubt, this section is intended to provide that Celera is
compensated for a Celera-related Tax Asset that remains with the Applera Group
after the Split-Off Date only if and to the extent that Celera would have been
able to utilize such Tax Asset on or before the time that the Applera Group
actually utilizes such Tax Asset.  For
the avoidance of doubt, this section shall apply to any gain related to
Exchange Taxes in the same manner as it applies to any other income or gains.

 

3.07.  Payment of Tax Liability.  If one Party is liable or responsible for
Taxes, under Sections 3.01 through 3.06, with respect to Tax Returns for which
another party is responsible 

 

11

 

for
preparing and/or filing, or with respect to Taxes that are paid by another
Party, then the liable or responsible Party shall pay the Taxes (or a
reimbursement of such Taxes) to the other Party pursuant to Section 7.05.

 

                3.08.  Computation.  With respect to any Tax Return filed by
Applera for which Celera is liable for Taxes under this Section 3, Applera
shall provide Celera with a written calculation in reasonable detail (including
copies of work sheets and other materials used in preparation thereof) setting
forth the amount of any Celera Separate Tax Amount or estimated Celera Separate
Tax Amount (for purposes of Section 7.01). 
Celera shall have the right to review and comment on such
calculation.  Any dispute with respect to
such calculation shall be resolved pursuant to Section 9.03; provided,
however, that, notwithstanding any dispute with respect to any such
calculation, in no event shall any payment attributable to the amount of any
Celera Separate Tax Amount or estimated Celera Separate Tax Amount be paid
later than the date provided in Section 7.

 

Section 4.              Exchange
Taxes, Contribution Taxes and Deconsolidation.

 

4.01.  Exchange Taxes.

 

(a) 
Applera’s Liability for Exchange Taxes. 
Notwithstanding Sections 3.01 through 3.03, Applera and each Applera
Affiliate shall be jointly and severally liable for any Exchange Taxes
attributable to, caused by, or resulting from, one or more of the following:

 

(i)  any action or omission by Applera (or any
Applera Affiliate) inconsistent with any material, information, covenant or
representation related to Applera, any Applera Affiliate, or the Applera
Business in an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling
Documents or Ruling (for the avoidance of doubt, disclosure of any action or
fact that is inconsistent with any material, information, covenant or
representation submitted to Tax Counsel, the IRS, or other Taxing Authority, as
applicable, in connection with an Officer’s Certificate, Tax Opinion,
Supplemental Tax Opinion, Ruling Documents or Ruling shall not relieve Applera
(or any Applera Affiliate) of liability under this Agreement);

 

(ii) 
any action or omission by Applera (or any Applera Affiliate), after the
Split-Off (including any act or omission that is in furtherance of, connected
to, or part of a plan or series of related transactions (within the meaning of
section 355(e) of the Code) occurring on or prior to the Split-Off), including
a cessation, transfer to affiliates, or disposition of its active trades or
businesses, stock buyback or payment of an extraordinary dividend;

 

(iii) 
any acquisition of any stock or assets of Applera (or any Applera Affiliate) by
one or more other persons (other than Celera or a Celera Affiliate) prior to or
following the Split-Off; or

 

(iv) any
issuance of stock by Applera (or any Applera Affiliate), including any issuance
pursuant to the exercise of employee stock options or other employment related
arrangements or the exercise of warrants, or change in ownership of stock in
Celera (or any Celera Affiliate).

 

12

 

(b) 
Celera’s Liability for Exchange Taxes. 
Notwithstanding Sections 3.01 through 3.03, Celera and each Celera
Affiliate shall be jointly and severally liable for any Exchange Taxes
attributable to, caused by, or result from, one or more of the following:

 

(i)  any action or omission by Celera (or any
Celera Affiliate) after the Split-Off at any time, that is inconsistent with
any material, information, covenant or representation related to Celera, any
Celera Affiliate, or the Celera Business in an Officer’s Certificate, Tax
Opinion, Supplemental Tax Opinion, Ruling Documents or Ruling (for the
avoidance of doubt, disclosure by Celera (or any Celera Affiliate) to Applera
(or any Applera Affiliate) of any action or fact that is inconsistent with any
material, information, covenant or representation submitted to Tax Counsel, the
IRS, or other Taxing Authority, as applicable, in connection with an Officer’s
Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents or Ruling
shall not relieve Celera (or any Celera Affiliate) of liability under this
Agreement);

 

(ii) 
any action or omission by Celera (or any Celera Affiliate), after the Split-Off
Date (including any act or omission that is in furtherance of, connected to, or
part of a plan or series of related transactions (within the meaning of section
355(e) of the Code) occurring on or prior to the Split-Off Date) including
a cessation, transfer to affiliates or disposition of the active trades or
businesses, stock buyback or payment of an extraordinary dividend;

 

(iii) 
any acquisition of any stock or assets of Celera (or any Celera Affiliate) by
one or more other persons (other than Applera or any Applera Affiliate)
following the Split-Off; or

 

(iv) 
any issuance of stock by Celera (or any Celera Affiliate) after the Split-Off,
including any issuance pursuant to the exercise of employee stock options or other
employment related arrangements or the exercise of warrants, or change in
ownership of stock in Celera (or any Celera Affiliate) after the Split-Off.

 

(c) Joint
Liability for Remaining Exchange Taxes. 
Applera and each Applera Affiliate shall be liable for the Applera
Sharing Percentage and Celera and each Celera Affiliate shall be jointly and
severally liable for the Celera Sharing Percentage of any Exchange Taxes
(including costs related or attributable to such Exchange Taxes) not otherwise
allocated by Sections 4.01(a) or (b) (e.g., because of a retroactive
change in law).

 

(d) Representation.  Each of Applera and Celera represents that,
as of the date of this Agreement, neither it nor its Affiliates know of any
fact (other than the Proposed Merger) that may cause the Exchange to fail to
qualify under section 355 or section 368(a)(1)(D) of the Code.

 

13

 

4.02.  Continuing Covenants.

 

(a) 
In General.  Each of Applera (for
itself and each Applera Affiliate) and Celera (for itself and each Celera
Affiliate) agrees (1) not to take any action reasonably expected to result
in an increased Tax liability to the other, a reduction in a Tax Asset of the
other or an increased liability to the other under this Agreement, and (2) to
take any action reasonably requested by the other that would reasonably be
expected to result in a Tax Benefit or avoid a Tax Detriment to the other,
provided, in either such case, that the taking or refraining to take such
action does not result in any additional cost not fully compensated for by the
other Party or any other adverse effect to such Party.  The Parties hereby acknowledge that the
preceding sentence is not intended to limit, and therefore shall not apply to,
the rights of the Parties with respect to matters otherwise covered by this
Agreement.

 

(b) 
Celera Restrictions.  Celera
agrees that it will not knowingly take or fail to take, or permit any Celera
Affiliate to knowingly take or fail to take, any action where such action or
failure to act would be inconsistent with any material, information, covenant
or representation that relates to facts or matters related to Celera (or any
Celera Affiliate) or within the control of Celera and is contained in an
Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents
or Ruling (except where such material, information, covenant or representation
was not previously disclosed to Celera) other than as permitted by this Section 4.02.  For this purpose an action is considered
inconsistent with a representation if the representation states that there is
no plan or intention to take such action. 
Celera agrees that it will not take (and it will cause the Celera
Affiliates to refrain from taking) any position on a Tax Return that is
inconsistent with the treatment of the Exchange as transactions in which no
income, gain, or loss is recognized pursuant to section 355 of the Code.

 

(c) 
Applera Restrictions.  Applera
agrees that it will not knowingly take or fail to take, or permit any Applera
Affiliate to knowingly take or fail to take, any action where such action or
failure to act would be inconsistent with any material, information, covenant
or representation that relates to facts or matters related to Applera (or any
Applera Affiliate) or within the control of Applera and is contained in an
Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents
or Ruling other than as permitted by this Section 4.02.  For this purpose an action is considered
inconsistent with a representation if the representation states that there is
no plan or intention to take such action. 
Applera agrees that it will not take (and it will cause the Applera
Affiliates to refrain from taking) any position on a Tax Return that is inconsistent
with the treatment of the Exchange as transactions in which no income, gain, or
loss is recognized pursuant to section 355 of the Code.

 

(d) 
Certain Celera Actions Following the Split-Off.  Celera agrees that, during the two (2) year
period following the Split-Off, without first obtaining, at Celera’s own
expense, either a supplemental opinion from Tax Counsel that such action will
not result in Exchange Taxes (a “Supplemental Tax Opinion”) or a Ruling that
such action will not result in Exchange Taxes, unless in any such case Applera
and Celera agree otherwise in writing, Celera shall not (1) sell all or
substantially all of the assets of Celera or any Celera Affiliate, (2) merge
Celera, or any Celera Affiliate with another entity, without regard to which
party is the surviving entity, (3) transfer any assets of Celera in a
transaction described in section 351 (other than a transfer to a corporation
which files a consolidated return with Celera and which is wholly-owned,
directly or indirectly, by Celera) or subparagraph (C) or (D) of
section 368(a)(1) of the Code, (4) issue stock 

 

14

 

of
Celera or any Celera Affiliate (or any instrument that is convertible or
exchangeable into any such stock) in an acquisition or public or private
offering (excluding any issuance pursuant to the exercise of employee stock
options or other employment related arrangements having customary terms and
conditions and that satisfy the requirements of Treasury Regulations section
1.355-7(d)(8), or any successor provision thereto), or (5) facilitate or
otherwise participate in any acquisition of stock in Celera that would result
in any shareholder owning five percent (5%) or more of the outstanding stock of
Celera.  Celera (or any Celera Affiliate)
shall only undertake any of such actions after Applera’s receipt of such
Supplemental Tax Opinion or Ruling and pursuant to the terms and conditions of
any such Supplemental Tax Opinion or Ruling or as otherwise consented to in
writing in advance by Applera; provided, however, that if Celera
contemplates entering into a transaction described in this section and Celera
acknowledges in writing that it would have sole liability for any Exchange
Taxes under Section 4.01(b) that might arise from such transaction
and can demonstrate to the reasonable satisfaction of Applera that Celera can
satisfy its liability for any such Exchange Taxes, Applera shall consent to
Celera’s entering into such transaction without further restriction; and provided,
further, that in the event that (i) Applera completes a transaction
that results in a tax being imposed on Applera under Section 355(e) of
the Code (including without limitation the Proposed Merger), after such
completion, Celera shall no longer be subject to the restrictions under clause
4 and clause 5, or (ii) the Split-off is determined to be taxable, then
these restrictions shall no longer apply. 
The Parties hereby agree that they will act in good faith to take all
reasonable steps necessary to amend this Section 4.02(d), from time to
time, by mutual agreement, to (i) add certain actions to the list
contained herein, or (ii) remove certain actions from the list contained
herein, in either case, in order to reflect any relevant change in law,
regulation or administrative interpretation occurring after the date of this
Agreement.

 

(e) 
Notice of Specified Transactions. 
Not later than three (3) days after the public announcement
regarding any of the transactions described in Section 4.02(d) (including
a public announcement regarding Celera’s intent to enter into any such
transaction) Celera shall provide written notice of such transaction to
Applera.

 

4.03.  Other Taxes.

 

(a) 
Contribution Taxes. 
Notwithstanding Sections 3.01 through 3.03, but subject to Section 4.03(c),
if any Contribution Taxes are imposed on Applera or Celera, Applera and Celera
shall each be responsible for 50 percent of such Contribution Taxes.  For the avoidance of doubt, this equal
sharing of Contribution Taxes shall not be affected by the availability of any
corresponding deductions resulting from such Contribution Taxes.

 

(b) 
Big Dye Agreement Taxes. 
Notwithstanding Sections 3.01 through 3.03, but subject to Section 4.03(c),
the Parties intend to report the Big Dye Agreement as giving rise to current
taxable income to Applera, and corresponding current and future deductions to
Celera.  Celera shall pay to Applera (i) the
present value of the Tax benefit expected to be realized by Celera with respect
to such current and future deductions plus (ii) 50 percent of the
difference between (A) the Tax imposed on Applera resulting from the Big
Dye Agreement and (B) the present value of the Tax benefit expected to be
realized by Celera (as determined in 4.03(b)(i)).

 

15

 

(c) 
Treatment if Proposed Merger is Completed.  To the extent allowable under applicable law,
if the Proposed Merger is completed and results in the Split-off being taxable,
Applera and Celera shall report the entering into the IP Access Agreements as
taxable transactions for U.S. federal income tax purposes and the
indemnification provisions in Section 4.03(a) and (b) shall not
apply.  In such an event, Applera shall
be responsible for the resulting tax imposed on Applera, and Celera shall pay
Applera 50 percent of the present value of the Tax benefit expected to be
realized by Celera with respect to current and future deductions resulting from
the Big Dye Agreement and the IP Access Agreement.

 

4.04.  Allocation of Tax Items.  All Tax computations for (1) any
Pre-Split-Off Periods ending on the Split-Off Date and (2) the immediately
following taxable period of Celera or any Celera Affiliate, shall be made
pursuant to the principles of section 1.1502-76(b) of the Treasury Regulations
or of a corresponding provision under the laws of other jurisdictions, as
reasonably determined by Applera, taking into account all reasonable
suggestions made by Celera with respect thereto.

 

4.05.  Allocation of Tax Assets.

 

(a) 
In General.  In connection with
the Split-Off, Applera and Celera have set forth on Schedule 4.5 the Tax Assets
allocated to Applera and Celera, and each of Applera and Celera agrees that
each shall prepare all Tax Returns in a manner consistent with such allocation,
unless otherwise required by law.  The
Parties hereby agree that to the extent that Tax Assets are not shown in
Schedule 4.5, such Tax Assets were incurred by Applera and shall remain with
Applera.

 

(b) 
Earnings and Profits.  Applera
will advise Celera in writing of the decrease in Applera earnings and profits
attributable to the Split-Off under section 312(h) of the Code on or
before the first anniversary of the Split-Off Date; provided, however,
that Applera shall provide Celera with estimates of such amounts (determined in
accordance with past practice) prior to such anniversary as reasonably
requested by Celera.

 

Section 5.              Employee
Wages.

 

At
Applera’s request, Celera shall assume the Form W-2 and Form W-3
reporting obligations (including the filing of all forms necessary to comply
with magnetic media reporting requirements) of Applera with respect to any
employee of the Celera Business that Celera or any Celera Affiliate employs
during the calendar year which includes the Split-Off Date consistent with the
procedures set forth in section 5 of Rev. Proc. 2004-53, 2004-34 I.R.B. 320.

 

Section 6.              Indemnification.

 

6.01.  In General.  Applera and each member of the Applera Group
shall jointly and severally indemnify Celera, each Celera Affiliate, and their
respective directors, officers and employees, and hold them harmless from and
against any and all Taxes for which Applera or any Applera Affiliate is liable
under this Agreement and any loss, cost, damage or expense, including
reasonable attorneys’ fees and costs, that is attributable to, or results from,
the failure of Applera, 

 

16

 

any
Applera Affiliate or any director, officer or employee to make any payment
required to be made under this Agreement. 
Celera and each member of the Celera Group shall jointly and severally
indemnify Applera, each Applera Affiliate, and their respective directors,
officers and employees, and hold them harmless from and against any and all
Taxes for which Celera or any Celera Affiliate is liable under this Agreement
and any loss, cost, damage or expense, including reasonable attorneys’ fees and
costs, that is attributable to, or results from, the failure of Celera, any
Celera Affiliate or any director, officer or employee to make any payment
required to be made under this Agreement.

 

6.02.  Inaccurate or Incomplete Information.  Applera and each member of the Applera Group
shall jointly and severally indemnify Celera, each Celera Affiliate, and their
respective directors, officers and employees, and hold them harmless from and
against any cost, fine, penalty, or other expense of any kind attributable to
the failure of Applera or any Applera Affiliate in supplying Celera or any
Celera Affiliate with inaccurate or incomplete information, in connection with
the preparation of any Tax Return. 
Celera and each member of the Celera Group shall jointly and severally
indemnify Applera, each Applera Affiliate, and their respective directors,
officers and employees, and hold them harmless from and against any cost, fine,
penalty, or other expenses of any kind attributable to the failure of Celera or
any Celera Affiliate in supplying Applera or any Applera Affiliate with
inaccurate or incomplete information, in connection with the preparation of any
Tax Return.

 

6.03.  No Indemnification for Tax Items.  Nothing in this Agreement shall be construed
as a guarantee of the existence or amount of any loss, credit, carryforward,
basis or other Tax Item, whether past, present or future, of Applera, any Applera
Affiliate, Celera or any Celera Affiliate. 
In addition, for the avoidance of doubt, for purposes of determining any
amount owed between the Parties hereto, all such determinations shall be made
without regard to any financial accounting tax asset or liability or other
financial accounting items.

 

Section 7.              Payments.

 

7.01.  Estimated Tax Payments.  Not later than ten (10) business days
after each Estimated Tax Installment Date with respect to a taxable period for
which a Consolidated Return or a Combined Return that includes a Celera
Separate Tax Amount will be filed, Celera shall pay to Applera on behalf of the
Celera Group an amount equal to the amount of any estimated Celera Separate Tax
Amount.

 

7.02.  True-Up Payments.  Not later than ten (10) business days
after filing a Tax Return, Celera shall pay to Applera, or Applera shall pay to
Celera, as appropriate, an amount equal to the difference, if any, between the
Celera Separate Tax Amount and the aggregate amount paid by Celera with respect
to such period under Section 7.01.

 

7.03.  Redetermination Amounts.  In the event of a redetermination of any Tax
Item reflected on any Consolidated Return or Combined Return (other than Tax
Items relating to Exchange Taxes), as a result of a refund of Taxes paid, a
Final Determination or any settlement or compromise with any Taxing Authority
which in any such case would affect the Celera Separate Tax Amount, Applera
shall prepare a revised pro forma Tax Return in accordance with 

 

17

 

Section 2.04(b) for
the relevant taxable period reflecting the redetermination of such Tax Item as
a result of such refund, Final Determination, settlement or compromise.  Celera shall pay to Applera, or Applera shall
pay to Celera, as appropriate, an amount equal to the difference, if any,
between the Celera Separate Tax Amount reflected on such revised pro forma Tax
Return and the Celera Separate Tax Amount for such period as originally
computed pursuant to this Agreement.

 

7.04.  Payments of Refunds and Credits.  If one Party receives a refund or credit of
any Tax to which the other Party is entitled pursuant to Section 3.04, the
Party receiving such refund or credit shall pay to the other Party the amount
of such refund or credit pursuant to Section 7.05.

 

7.05.  Payments Under This Agreement.  In the event that one Party (the “Owing Party”)
is required to make a payment to another Party (the “Owed Party”) pursuant to
this Agreement, then such payments shall be made according to this Section 7.05.

 

(a) 
In General.  All payments shall be
made to the Owed Party or to the appropriate Taxing Authority as specified by
the Owed Party within the time prescribed for payment in this Agreement, or if
no period is prescribed, within ten (10) days after delivery of written
notice of payment owing together with a computation of the amounts due.

 

(b) 
Treatment of Payments.  Unless
otherwise required by any Final Determination, the Parties agree that any
payments made by one Party to another Party pursuant to this Agreement (other
than (i) payments for the Celera Separate Tax Amount for the
Post-Split-Off Period, (ii) payments of After Tax Amounts pursuant to Section 7.05(d),
and (iii) payments of interest pursuant to Section 7.05(e)) shall be
treated for all Tax purposes as nontaxable payments (dividend distributions or
capital contributions, as the case may be) made immediately prior to the
Split-Off and, accordingly, as not includible in the taxable income of the
recipient or as deductible by the payor.

 

(c) 
Prompt Performance.  All actions
required to be taken (including payments) by any Party under this Agreement
shall be performed within the time prescribed for performance in this
Agreement, or if no period is prescribed, such actions shall be performed
promptly.

 

(d) 
After Tax Amounts.  If pursuant to
a Final Determination it is determined that the receipt or accrual of any
payment made under this Agreement (other than payments of interest pursuant to Section 7.05(e))
is subject to any Tax, the Party making such payment shall be liable for (a) the
After Tax Amount with respect to such payment and (b) interest at the rate
described in Section 7.05(e) on the amount of such Tax from the date
such Tax accrues through the date of payment of such After Tax Amount.  A Party making a demand for a payment
pursuant to this Agreement and for a payment of an After Tax Amount with
respect to such payment shall separately specify and compute such After Tax
Amount.  However, a Party may choose not
to specify an After Tax Amount in a demand for payment pursuant to this
Agreement without thereby being deemed to have waived its right subsequently to
demand an After Tax Amount with respect to such payment.

 

18

 

(e) 
Interest.  Payments pursuant to
this Agreement that are not made within the period prescribed in this Agreement
(the “Payment Period”) shall bear interest for the period from and including
the date immediately following the last date of the Payment Period through and
including the date of payment at  a
per annum rate equal to the applicable rate under Section 6621 of the
Code.  Such interest will be payable at
the same time as the payment to which it relates and shall be calculated  on the basis of a year of three hundred
sixty-five (365) days and the actual number of days for which due.

 

Section 8.              Tax
Proceedings.

 

8.01.  In General.  Except as otherwise provided in this
Agreement, the Party responsible for preparing and filing a Tax Return pursuant
to Section 2 (the “Filing Party”) shall have the exclusive right, in its
sole discretion, to control, contest, and represent the interests of Applera,
any Applera Affiliate, Celera, and/or any Celera Affiliate in any Audit
relating to such Tax Return and to resolve, settle or agree to any deficiency,
claim or adjustment proposed, asserted or assessed in connection with or as a
result of any such Audit; provided, however, that for purposes of
this Section 8, Celera shall be treated as the Filing Party for all Tax
Returns of BHL and BHL Affiliates (other than Consolidated Returns or Combined
Returns).  The Filing Party’s rights
shall extend to any matter pertaining to the management and control of an
Audit, including execution of waivers, choice of forum, scheduling of
conferences and the resolution of any Tax Item. 
Any costs incurred in handling, settling, or contesting an Audit shall
be borne by the Filing Party.

 

8.02.  Participation of non-Filing Party.  Except as provided in Section 8.04, the
non-Filing Party shall, at its own expense, have control over decisions to
resolve, settle or otherwise agree to any deficiency, claim or adjustment with
respect to any Sole Responsibility Item. 
Except as provided in Section 8.04, the Filing Party, at its own
expense, and the non-Filing Party, at its own expense, shall have joint control
over decisions to resolve, settle or otherwise agree to any deficiency, claim
or adjustment with respect to any Joint Responsibility Item.  Except as provided in Section 8.04, the
Filing Party shall not settle any Audit it controls concerning a Tax Item on a
basis that would reasonably be expected to adversely affect the non-Filing
Party by at least one hundred thousand dollars ($100,000) without obtaining
such non-Filing Party’s consent, which consent shall not be unreasonably
withheld, conditioned or delayed if failure to consent would adversely affect
the Filing Party.

 

8.03.  Notice.  Within ten (10) days after a Party
receives written notice of a proposed Audit adjustment that may give rise to an
indemnification obligation under this Agreement, such Party shall give notice
to the other Party of such issue (such notice shall contain factual
information, to the extent known, describing any asserted tax liability in
reasonable detail), and shall forward to the other Party copies of all notices
and material communications with any Taxing Authority relating to such
issue.  Notwithstanding any provision in Section 9.15
to the contrary, if a Party to this Agreement fails to provide the other Party
notice as required by this Section 8.03, and the failure results in a
detriment to the other Party then any amount which the other Party is otherwise
required to pay pursuant to this Agreement shall be reduced by the amount of
such detriment.

 

19

 

8.04.  Control of Exchange Tax and Contribution
Tax Proceedings.  Applera shall have
the exclusive right, in its sole discretion, to control, contest, and represent
the interests of Applera, any Applera Affiliate, Celera, and/or any Celera
Affiliate in any Audits relating to Exchange Taxes and Contribution Taxes and
to resolve, settle or agree to any deficiency, claim or adjustment proposed,
asserted or assessed in connection with or as a result of any such Audit; provided,
however, that Applera shall not settle any such audit with respect to
Exchange Taxes or Contribution Taxes with a Taxing Authority as part of a
formal understanding with the Taxing Authority for a settlement on an issue or
issues unrelated to such Exchange Taxes or Contribution Taxes that would
reasonably be expected to result in a Tax liability to Celera or any Celera
Affiliate (including as a result of an indemnification obligation pursuant to
this Agreement) in excess of one hundred thousand dollars ($100,000), without
the prior consent of Celera, which consent shall not be unreasonably withheld,
conditioned or delayed.  Applera’s rights
shall extend to any matter pertaining to the management and control of such
Audit, including execution of waivers, choice of forum, scheduling of
conferences and the resolution of any Tax Item. 
Celera may assume sole control of any Audits relating to Exchange Taxes
if it acknowledges in writing that it has sole liability for any Exchange Taxes
under Section 4.01(b) that might arise in such Audit and can
demonstrate to the reasonable satisfaction of Applera that it can satisfy its
liability for any such Exchange Taxes. 
If Celera is unable to demonstrate to the reasonable satisfaction of
Applera that it will be able to satisfy its liability for such Exchange Taxes,
but acknowledges in writing that it has sole liability for any Exchange Taxes
under Section 4.01(b), Celera and Applera shall have joint control over
the Audit.

 

Section 9.              Miscellaneous
Provisions.

 

9.01.  Effectiveness.  This Agreement shall become effective upon
execution by the Parties hereto.

 

9.02.  Cooperation and Exchange of Information.

 

(a) 
Cooperation.  Celera and Applera
shall each cooperate fully (and each shall cause its respective affiliates to
cooperate fully) with all reasonable requests from another party for
information and materials not otherwise available to the requesting party in
connection with the preparation and filing of Tax Returns, claims for refund,
and Audits concerning issues or other matters covered by this Agreement or in
connection with the determination of a liability for Taxes or a right to a
refund of Taxes.  Such cooperation shall
include:

 

(i) the
retention until the expiration of the applicable statute of limitations, and
the provision upon request, of copies of all Tax Returns, books, records
(including information regarding ownership and Tax basis of property),
documentation and other information relating to the Tax Returns, including
accompanying schedules, related work papers, and documents relating to rulings
or other determinations by Taxing Authorities;

 

(ii) the
execution of any document that may be necessary or reasonably helpful in
connection with any Tax Proceeding, or the filing of a Tax Return or refund
claim by a member of the Applera Group or the Celera Group, including
certification, to the best of a Party’s knowledge, of the accuracy and
completeness of the information it has supplied; and

 

20

 

(iii)       the use of the
Party’s commercially reasonable efforts to obtain any documentation that may be
necessary or reasonably helpful in connection with any of the foregoing.  Each Party shall make its employees and
facilities available on a reasonable and mutually convenient basis in
connection with the foregoing matters.

 

(b) 
Retention of Records.  Any Party
that is in possession of documentation of Applera (or any Applera Affiliate) or
Celera (or any Celera Affiliate) relating to the Celera Business, including
books, records, Tax Returns and all supporting schedules and information
relating thereto (the “Celera Business Records”) shall retain such Celera
Business Records for a period of seven (7) years following the Exchange
Date.  Thereafter, any Party wishing to
dispose of Celera Business Records in its possession (after the expiration of
the applicable statute of limitations), shall provide written notice to the
other Party describing the documentation proposed to be destroyed or disposed
of sixty (60) business days prior to taking such action.  The other Party may arrange to take delivery
of any or all of the documentation described in the notice at its expense
during the succeeding sixty (60) day period.

 

9.03.              Dispute Resolution.  Except with respect to Exchange Taxes, all
disputes under this agreement shall be controlled by Section 13.3 of the
Separation Agreement.  Notwithstanding
the foregoing, any disagreement between the Parties relating to Exchange Taxes
shall be settled in a court of law or as otherwise agreed to by the Parties.

 

9.04.              Notices.  All notices and other communications required
or permitted to be given hereunder shall be in writing and shall be deemed
given upon (a) a transmitter’s confirmation of a receipt of a facsimile
transmission (but only if followed by confirmed delivery of a standard
overnight courier the following business day or if delivered by hand the
following business day), (b) confirmed delivery of a standard overnight
courier or when delivered by hand, or (c) the expiration of five (5) business
days after the date mailed by certified or registered mail (return receipt
requested), postage prepaid, to the Parties at the following addresses (or at
such other addresses for a Party as shall be specified by like notice):

 

If
to Applera or any Applera Affiliate, to the Vice President, Tax of Applera,
with a copy to the General Counsel of Applera, at:

 

Applera
Corporation

301
Merritt 7

Norwalk,
Connecticut 06851

 

If
to Celera or any Celera Affiliate, to the General Counsel of Celera, at:

 

Celera
Corporation

1401
Harbor Bay Parkway

Alameda,
California 94502

 

Either
Party may, by written notice to the other Parties, change the address or the
Party to which any notice, request, instruction or other documents is to be
delivered.

 

21

 

9.05.              Changes in Law.

 

(a) 
Any reference to a provision of the Code or a law of another jurisdiction shall
include a reference to any applicable successor provision or law.

 

(b) 
If, due to any change in applicable law or regulations or their interpretation
by any court of law or other governing body having jurisdiction subsequent to
the date of this Agreement, performance of any provision of this Agreement or
any transaction contemplated thereby shall become impracticable or impossible,
the Parties hereto shall use their commercially reasonable efforts to find and
employ an alternative means to achieve the same or substantially the same
result as that contemplated by such provision.

 

9.06.              Confidentiality.  The Parties shall comply with the
confidentiality provisions in section 13.9 of the Separation Agreement.

 

9.07.              Successors.  This Agreement shall be binding on and inure
to the benefit and detriment of any successor, by merger, acquisition of assets
or otherwise, to any of the Parties hereto, to the same extent as if such
successor had been an original party.

 

9.08.              Affiliates.  Applera shall cause to be performed, and
hereby guarantees the performance of, all actions, agreements and obligations
set forth herein to be performed by any Applera Affiliate, and Celera shall
cause to be performed, and hereby guarantees the performance of, all actions,
agreements and obligations set forth herein to be performed by any Celera
Affiliate; provided, however, that (1) if it is contemplated
that a Celera Affiliate may cease to be a Celera Affiliate as a result of a
transfer of its stock or other ownership interests to a third party in exchange
for consideration in an amount approximately equal to the fair market value of
the stock or other ownership interests transferred and such consideration is
not distributed outside of the Celera Group to the shareholders of Celera then (a) Celera
shall request in writing no later than thirty (30) days prior to such cessation
that Applera execute a release of such Celera Affiliate from its obligations
under this Agreement effective as of such transfer provided that Celera shall
have confirmed in writing its obligations and the obligations of its remaining
Celera Affiliates with respect to their own obligations and those of the
departing Celera Affiliate and that such departing Celera Affiliate shall have
executed a release of any rights it may have against Applera or any Applera
Affiliate by reason of this Agreement, or (b) Celera shall acknowledge in
writing no later than thirty (30) days prior to such cessation that it shall
bear one hundred percent (100%) of the liability for the obligations of Celera
and each Celera Affiliate (including the departing Celera Affiliate) under this
Agreement and (2) if it is contemplated that an Applera Affiliate may
cease to be an Applera Affiliate as a result of a transfer of its stock or
other ownership interests to a third party in exchange for consideration in an
amount approximately equal to the fair market value of the stock or other
ownership interests transferred and such consideration is not distributed
outside of the Applera Group to the shareholders of Applera then (a) Applera
shall request in writing no later than thirty (30) days prior to such cessation
that Celera execute a release of such Applera Affiliate from its obligations
under this Agreement effective as of such transfer provided that Applera shall
have confirmed in writing its obligations and the obligations of its remaining Applera
Affiliates with respect to their 

 

22

 

own
obligations and the obligations of the departing Applera Affiliate and that
such departing Applera Affiliate shall have executed a release of any rights it
may have against Celera or any Celera Affiliate by reason of this Agreement, or
(b) Applera shall acknowledge in writing no later than thirty (30) days
prior to such cessation that it shall bear one hundred percent (100%) of the
liability for the obligations of Applera and each Applera Affiliate (including
the departing Applera Affiliate) under this Agreement.  If at any time (1) Applera shall,
directly or indirectly, obtain beneficial ownership of more than fifty percent
(50%) of the total combined voting power of any other entity, Applera shall
cause such entity to become a party to this Agreement by executing together
with Celera an agreement in substantially the same form as set forth in
Schedule 9.08 and such entity shall have all rights and obligations of an
Applera Affiliate under this Agreement, and (2) Celera shall, directly or
indirectly, obtain beneficial ownership of more than fifty percent (50%) of the
total combined voting power of any other entity, Celera shall cause such entity
to become a party to this Agreement by executing together with Applera an
agreement in substantially the same form as set forth in Schedule 9.08 and such
entity shall have all rights and obligations of a Celera Affiliate under this
Agreement.

 

9.09.              Authorization, Etc.  Each of the Parties hereto hereby represents
and warrants that it has the power and authority to execute, deliver and
perform this Agreement, that this Agreement has been duly authorized by all
necessary corporate action on the part of such Party, that this Agreement
constitutes a legal, valid and binding obligation of each such Party and that
the execution, delivery and performance of this Agreement by such Party does
not contravene or conflict with any provision of law or of its charter or
bylaws or any agreement, instrument or order binding on such Party.

 

9.10.              Entire Agreement.  This Agreement contains the entire agreement
among the Parties hereto with respect to the subject matter hereof and
supersedes any prior tax sharing agreements between Applera (or any Applera
Affiliate) and Celera (or any Celera Affiliate) and such prior tax sharing
agreements shall have no further force and effect.  If, and to the extent, the provisions of this
Agreement conflict with any agreement entered into in connection with the
Split-Off, the provisions of this Agreement shall control.

 

9.11.              Applicable Law; Jurisdiction.  EACH OF THE PARTIES TO THIS AGREEMENT HEREBY
IRREVOCABLY AND UNCONDITIONALLY (i) AGREES THAT THIS AGREEMENT SHALL BE
CONSTRUED IN ACCORDANCE WITH AND ALL DISPUTES CONTROVERSIES OR CLAIMS ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE BREACH, TERMINATION OR VALIDITY
HEREOF SHALL BE GOVERNED BY THE LAWS OF THE STATE OF DELAWARE, EXCLUDING ITS
CONFLICTS OF LAW RULES, (ii) AGREES TO BE SUBJECT TO, AND HEREBY CONSENTS
AND SUBMITS TO, THE JURISDICTION OF THE COURTS OF THE STATE OF DELAWARE AND OF
THE FEDERAL COURTS SITTING IN THE STATE OF DELAWARE, (iii) TO THE EXTENT
SUCH PARTY IS NOT OTHERWISE SUBJECT TO SERVICE OF PROCESS IN THE STATE OF
DELAWARE, HEREBY APPOINTS THE CORPORATION TRUST COMPANY, AS SUCH PARTY’S AGENT
IN THE STATE OF DELAWARE FOR ACCEPTANCE OF LEGAL PROCESS, AND (iv) AGREES
THAT SERVICE MADE ON ANY SUCH AGENT SET FORTH IN (iii) ABOVE SHALL HAVE 

 

23

 

THE
SAME LEGAL FORCE AND EFFECT AS IF SERVED UPON SUCH PARTY PERSONALLY WITHIN THE
STATE OF DELAWARE.

 

9.12.              Counterparts.  This Agreement may be executed in any number
of counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same Agreement.

 

9.13.              Severability.  If any term, provision, covenant, or
restriction of this Agreement is held by a court of competent jurisdiction (or
an arbitrator or arbitration panel) to be invalid, void, or unenforceable, the
remainder of the terms, provisions, covenants, and restrictions set forth
herein shall remain in full force and effect, and shall in no way be affected,
impaired, or invalidated.  In the event
that any such term, provision, covenant or restriction is held to be invalid,
void or unenforceable, the Parties hereto shall use commercially reasonable
efforts to find and employ an alternate means to achieve the same or
substantially the same result as that contemplated by such terms, provisions,
covenant, or restriction.

 

9.14.              No Third Party Beneficiaries.  This Agreement is solely for the benefit of
Applera, the Applera Affiliates, Celera and the Celera Affiliates.  This Agreement should not be deemed to confer
upon third parties any remedy, claim, liability, reimbursement, cause of action
or other rights in excess of those existing without this Agreement.

 

9.15.              Waivers, Etc.  No failure or delay on the part of a Party in
exercising any power or right hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise of any such right or power, or any
abandonment or discontinuance of steps to enforce such right or power, preclude
any other or further exercise thereof or the exercise of any other right or
power.  No modification or waiver of any
provision of this Agreement nor consent to any departure by the Parties
therefrom shall in any event be effective unless the same shall be in writing,
and then such waiver or consent shall be effective only in the specific
instance and for the purpose for which given.

 

9.16.              Setoff.  All payments to be made by any Party under
this Agreement may be netted against payments due to such Party under this
Agreement, but otherwise shall be made without setoff, counterclaim or
withholding, all of which are hereby expressly waived.

 

9.17.              Other Remedies.  Celera recognizes that any failure by it or
any Celera Affiliate to comply with its obligations under Section 4 could
result in Exchange Taxes that would cause irreparable harm to Applera, Applera
Affiliates, and their stockholders. 
Accordingly, Applera shall be entitled to an injunction or injunctions
to prevent breaches of this Agreement and to enforce specifically the terms and
provisions of this Agreement, this being in addition to any other remedy to which
Applera is entitled at law or in equity.

 

9.18.              Amendment and Modification.  This Agreement may be amended, modified or
supplemented only by a written agreement signed by all of the Parties hereto.

 

9.19.              Waiver of Jury Trial.  Each of the Parties hereto irrevocably and
unconditionally waives all right to trial by jury in any litigation, claim,
action, suit, arbitration, inquiry, 

 

24

 

proceeding,
investigation or counterclaim (whether based in contract, tort or otherwise)
arising out of or relating to this Agreement or the actions of the Parties
hereto in the negotiation, administration, performance and enforcement thereof.

 

9.20. Interpretations.  The headings contained in this Agreement are
for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. 
Whenever the words “include,” “includes” or “including” are used in this
Agreement they shall be deemed to be followed by the words “without limitation.”  The words “hereof,” “herein” and “herewith”
and words of similar import shall, unless otherwise stated, be construed to
refer to this Agreement as a whole and not to any particular provision of this
Agreement, and article, section, paragraph, Exhibit and schedule
references are to the articles, sections, paragraphs, exhibits and schedules of
this Agreement unless otherwise specified. 
The meaning assigned to each term defined herein shall be equally
applicable to both the singular and the plural forms of such term, and words
denoting any gender shall include all genders. 
Where a word or phrase is defined herein, each of its other grammatical
forms shall have a corresponding meaning. 
The Parties have participated jointly in the negotiation and drafting of
this Agreement.  In the event an
ambiguity or question of intent or interpretation arises, this Agreement shall
be construed as if drafted jointly by the Parties, and no presumption or burden
of proof shall arise favoring or disfavoring any Party by virtue of the
authorship of any provisions of this Agreement.

 

25

 

IN
WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be
executed by a duly authorized officer as of the date first above written.

 

	
   

  	
  Applera
  Corporation

  
	
   

  	
  on
  behalf of itself and each of the Applera Affiliates

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
  Name:

  	
  [name]

  
	
   

  	
  Title:

  	
  [title]

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Celera
  Corporation

  
	
   

  	
  on
  behalf of itself and each of the Celera Affiliates

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
  Name:

  	
  [name]

  
	
   

  	
  Title:

  	
  [title]

  

 

26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]